Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Summer 8-15-2017

Nuclear export factor 3 regulates the localization of small
nucleolar RNAs
Melissa Wanling Li
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Cell Biology Commons, and the Molecular Biology Commons

Recommended Citation
Li, Melissa Wanling, "Nuclear export factor 3 regulates the localization of small nucleolar RNAs" (2017).
Arts & Sciences Electronic Theses and Dissertations. 1224.
https://openscholarship.wustl.edu/art_sci_etds/1224

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Molecular Cell Biology
Dissertation Examination Committee
Jean Schaffer, Chair
Thomas Baranski
Joseph Dougherty
Scot Matkovich
Jeanne Nerbonne
Joel Schilling

Nuclear export factor 3 regulates the localization of small nucleolar RNAs
By
Melissa Wanling Li

A dissertation presented to
The Graduate School
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

August 2017
Saint Louis, Missouri

© 2017, Melissa Wanling Li

Table of Contents
List of Figures………………………………………………………………………………...... iv
List of Tables…………………………………………………………………………………… v
Acknowledgments……………………………………………………………………………... vi
Abstract…………………………………………………………………………………………. x
CHAPTER ONE: Introduction to Lipotoxicity
1.1 Obesity and diabetes are global health concerns………………………………….. 1
1.2 Systemic metabolic abnormalities in diabetes……………………………………… 2
1.3 Liptoxicity……………………………………………………………………………….. 4
1.4 Rpl13a snoRNAs mediate cellular response to metabolic and oxidative stress... 7
1.5 Small nucleolar RNAs…………………………………………………………………. 9
1.6 RNA transporters……………………………………………………………..………. 11
CHAPTER TWO: Metabolic stress regulates snoRNA trafficking
2.1 Introduction……………………………………………………………………………. 15
2.2 Results…...……………………………………………………………………………. 16
2.2.1 Doxorubicin treatment increases cytosolic Rpl13a snoRNA levels in
cardiomyoblasts………………………………………………………………...… 16
2.2.2 Superoxide is necessary for cytosolic Rpl13a snoRNA accumulation
during doxorubicin treatment……………………………………………………. 17
2.2.3 NADPH oxidase 4 mediates cytosolic accumulation of Rpl13a snoRNAs in
response to doxorubicin treatment…………………………………………...… 18
2.2.4 SnoRNAs are dynamically regulated in the cytoplasm…………………...….. 19
2.3 Conclusions…………………………………………………………………………… 21
2.4 Figures………………………………………………………………………………… 22
CHAPTER THREE: NXF3 functions as a nucleocytoplasmic snoRNA transporter
3.1 Introduction……………………………………………………………………………. 32
3.2 Results……………………………………………………………………………….... 33
3.2.1 NXF3 knockdown protects against lipotoxic cell death in endothelial cells… 33
3.2.2 NXF3 knockdown endothelial cells have aberrant Rpl13a snoRNA
localization……………………………………………………………………….... 34
3.2.3 Knockdown of NXF3 increases cytosolic Rpl13a snoRNA in
cardiomyoblasts…………………………………………………………………... 35
3.2.4 Overexpression of NXF3 decreases cytosolic Rpl13a snoRNA in
fibroblasts…………………………………………………………………………. 36
3.2.5 NXF3 and NXF1 associate with snoRNAs…………………………………….. 37
3.3 Conclusions…………………………………………………………………………… 39

ii

3.4 Figures………………………………………………………………………………… 41
CHAPTER FOUR: NXF3 as a point of regulation of transport
4.1 Introduction……………………………………………………………………………. 53
4.2 Results……………………………………………………………………………….... 54
4.2.1 Forskolin decreases cytosolic Rpl13a snoRNA levels and increases
NXF3-Rpl13a snoRNA association…………………………………………….. 54
4.2.2 NXF3 phosphorylation does not change during forskolin treatment……...… 55
4.2.3 Doxorubicin increases cytosolic snoRNAs and decreases NXF3-Rpl13a
snoRNA association……………………………………………………………… 55
4.2.4 Forskolin effect on snoRNA localization is dependent on NXF3……………. 56
4.3 Conclusions…………………………………………………………………………… 57
4.4 Figures………………………………………………………………………………… 58
CHAPTER FIVE: Summary and Discussion
5.1 Summary………………………………………………………………………………. 67
5.2 Cytosolic snoRNAs…………………………………………………………………… 67
5.3 NXF3 as a snoRNA transporter…………………………………………………..… 69
5.4 Regulation of NXF3-mediated snoRNA transport………………………………… 71
5.5 NXF3 and lipotoxicity………………………………………………………………… 73
CHAPTER SIX: Materials and Methods…………………………………………………. 75
CHAPTER SEVEN: References…………………………………………………………… 80

iii

List of Figures
CHAPTER TWO
Figure 2.1 Doxorubicin treatment increases cytosolic Rpl13a snoRNA levels in
cardiomyoblasts………………………………………………………………. 22
Figure 2.2 Superoxide is necessary for cytosolic Rpl13a snoRNA accumulation
during doxorubicin treatment……………………………………………...… 24
Figure 2.3 Exonic structure of NOX4A and alternatively splice nuclear form
NOX4D………………………………………………………………………… 25
Figure 2.4 NADPH oxidase 4D mediates cytosolic accumulation of Rpl13a snoRNAs
in response to doxorubicin treatment………………………………………. 26
Figure 2.5 SnoRNAs are dynamically regulated in the cytoplasm…………………... 28
Figure 2.6 Model for cytoplasmic snoRNA regulation………………………………… 31
CHAPTER THREE
Figure 3.1 Knockdown of NXF3 protects against lipotoxic cell death in endothelial
Cells…………………………………………………………………………… 41
Figure 3.2 NXF3 knockdown alters Rpl13a snoRNA localization under basal growth
conditions in endothelial cells………………………………………………. 42
Figure 3.3 Knockdown and overexpression of NXF3 alters Rpl13a snoRNA
localization in cardiomyoblasts…………………………………………….. 44
Figure 3.4 Overexpression of NXF3 alters Rpl13a snoRNA localization in
fibroblasts…………………………………………………………………….. 46
Figure 3.5 NXF3- and NXF1-GFP can be immunoprecipitated using α-GFP…...… 48
Figure 3.6 NXF3 and NXF1 associate with snoRNAs……………………………......
489
CHAPTER FOUR
Figure 4.1 Forskolin decreases cytosolic Rpl13a snoRNA levels…………………... 58
Figure 4.2 Forskolin increases NXF3-GFP-snoRNA association and nuclear
localization of NXF3-GFP…………………………………………………… 60
Figure 4.3 Forskolin does not change NXF3-GFP phosphorylation levels……........ 61
Figure 4.4 Doxorubicin increases cytosolic snoRNAs and decreases NXF3
association with Rpl13a snoRNAs…………………………………………. 63
Figure 4.5 Forskolin effect on snoRNA localization is dependent on NXF3………... 65
Figure 4.6 Model for NXF3 function…………………………………………………..… 66

iv

List of Tables
CHAPTER TWO
Table 2.5A Cytoplasmic RNA-seq reads (total per condition)………………………… 30
CHAPTER THREE
Table 3.6A Quality of RNA sequencing data……………………………………………. 49
Table 3.6B Distribution of non-ribosomal RNA reads………………………………….. 50
Table 3.6C Most abundant immunoprecipitating snoRNAs…………........…………… 51

v

Acknowledgments
I would first like to thank my thesis mentor Dr. Jean Schaffer. Her relentless optimism
and constant support have helped me accomplish things I did not think possible when I
began my Ph.D. Her constructive criticism and attention to detail have not only made
me a better experimentalist and science communicator, but has also built my selfesteem and confidence that I can accomplish anything. I would also like to thank the
members of my thesis committee, Dr. Thomas Baranski, Dr. Joseph Dougherty, Dr.
Scot Matkovich, Dr. Jeanne Nerbonne, and Dr. Joel Schilling for always challenging me
to think critically and guiding me through my thesis these past six years. I would
especially like to thank Dr. Scot Matkovich for his guidance and help with analyzing my
RNA sequencing data.

I would not be here today without the support and collaboration of everyone in the
Schaffer and Ory labs. I would like to thank Dr. Dan Ory for his willingness to answer my
questions and provide input on my data. Words cannot express how grateful I am for
the camaraderie of my fellow past and present graduate students: Dr. Aggie Bielska, Dr.
Katrina Brandis, Dr. George Caputa, McKenna Feltes, Dr. Mia Henderson, Dr. Sarah
Jinn, Dr. Maria Praggastis, Dr. Ben Scruggs, and Artie Sletten. Talking about
experiments with them every day and getting their advice have been invaluable to me.
Besides the day-to-day science discussions, they have all been my support system both
inside and outside of lab. I will forever be grateful to Dr. Christopher Holley for his
mentorship during my Ph.D. He was not just a role model in the lab but life in general. I

vi

would like to thank Dr. Jiyeon Lee, Dr. Jamie Rimer, and Josh Langmade for their
willingness to drop whatever they were doing to help anyone with an experiment or
answer a question, no matter how small or big. I would also like to thank Sarah Gale
whose positive attitude fueled the lab. The Schaffer and Ory labs would have a hard
time functioning without you all. Even when science wasn’t going well, these people
made it worth it to continue to come into lab every day.

Thank you to all of the amazing friendships I have built during grad school. My friends
have made me a better person and the support system they have provided me has
been invaluable. I would not be who I am today without them. The times we have spent
together are some of the best highlights of my life.

I would also like to thank my boyfriend Nick. I am so fortunate that we met early in grad
school. Nick has listened to every complaint and every success I had in lab and his
ability to make me laugh and feel loved has gotten me through all the ups and downs for
the past six years. Thank you for being my constant reminder that life is good. My life
wouldn’t be the same without you.

Finally I would like to thank my family. My parents have sacrificed a lot to ensure I had
every opportunity possible and words can never describe how thankful I am. I strive to
be as thoughtful, generous and hard working as they are. They have always supported
me and given me guidance in every aspect of my life. I would also like to thank my
sister, Michelle. I am so fortunate to have a big sister who not only never hesitated to

vii

give me advice, celebrate my successes with me, and always agreed to take jumping
pictures with me, but she also has been my best friend through all stages of life. I am
also grateful to my brother-in-law Jesse for his insightful advice and for truly being a
brother to me. Their constant encouragement is why I am here today. Thank you for
always pushing me to reach my full potential.

Melissa Wanling Li

Washington University in St. Louis
August 2017

viii

Dedicated to my parents.

ix

ABSTRACT OF DISSERTATION
Nuclear export factor 3 regulates the localization of small nucleolar RNAs
By
Melissa Wanling Li
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2017
Professor Jean E. Schaffer, Chairperson
Metabolic diseases, such as obesity and diabetes, are associated with excess levels of
lipids, which can lead to organelle dysfunction, cell death and eventually organ
dysfunction. This process, termed lipotoxicity, is still not completely understood. In a
genetic screen used to identify genes critical for lipotoxicity, the Schaffer lab has
identified small nucleolar RNAs (snoRNAs) within the ribosomal protein L13a (Rpl13a)
locus that mediate the cellular response to lipotoxic and general metabolic stress.
These snoRNAs are non-canonical in that they accumulate in the cytosol after
metabolic stresses like lipotoxicity and oxidative stress, suggesting that cells have
specific mechanisms for regulating snoRNA distribution within the cell.

To begin elucidating the underlying mechanism of snoRNA transport from the nucleus
to the cytoplasm during metabolic stress, we modeled oxidative stress by treating cells
with the chemotherapeutic drug doxorubicin (DOX). DOX is a potent inducer of
superoxide through the activation of NADPH oxidase splice isoform 4D (NOX4D) and
results in the cytosolic accumulation of Rpl13a snoRNAs. NOX inhibitors and genetic

x

knockdown of NOX4D led to a decrease in the accumulation of Rpl13a snoRNAs in the
cytosol after DOX treatment. Furthermore, RNA-sequencing studies demonstrated that
snoRNAs as a class accumulated in the cytosol after DOX treatment, while
simultaneous treatment with NOX inhibitors blunted the increase in cytosolic levels of
snoRNAs. Together, these data indicate that snoRNAs as a class are present in the
cytoplasm, where their levels are dynamically regulated by NOX4D during oxidative
stress.

The finding that loss-of-function of NXF3, a member of the nuclear export family of RNA
transporters, protects cells from lipotoxic cell death suggested that this protein may
function as a regulator of snoRNA distribution. In transient transfection assays, NXF3
knockdown increased abundance of cytosolic Rpl13a snoRNAs, whereas NXF3
overexpression led to decreased cytosolic levels. These observations suggested that
snoRNAs traffic constitutively between the nucleus and cytoplasm, and NXF3 functions
to efficiently concentrate snoRNAs in the nucleus. Consistent with a role for NXF3 as a
snoRNA transporter, we found the Rpl13a snoRNAs co-immunoprecipitated with NXF3.
Treatment of cells with forskolin caused a rapid decrease in cytosolic snoRNAs and
increased both nuclear localization of NXF3 and association of NXF3 with Rpl13a
snoRNAs. These effects of forskolin were abrogated by NXF3 knockdown.

Our findings identify a novel trafficking pathway for snoRNAs that cycle between the
nucleus and the cytosol. This pathway is regulated by oxidative stress and levels of the
RNA transporter NXF3.

xi

CHAPTER ONE:
Introduction
1.1 Obesity and diabetes are global health concerns
Obesity is a major risk factor for metabolic diseases such as diabetes, and both have
become increasingly prevalent worldwide. Obesity has more than doubled since 1980.
In 2014, more than 1.9 billion adults were overweight, 600 million of whom were obese
and 422 million of whom were diagnosed with diabetes (WHO Diabetes fact sheet,
2016). These diseases have been attributed to accelerated urbanization, increased
caloric intake, changes in types of caloric intake, and sedentary lifestyles (WHO
Diabetes fact sheet, 2016; Globalization of Diabetes Hu, 2011).

Many complications can arise from obesity and diabetes, and these contribute to
substantial morbidity and mortality. Cardiovascular disease accounts for 51% of deaths
in patients with type 1 diabetes and 52% of deaths in patients with type 2 diabetes 1.
Diabetic heart diseases include coronary heart disease (CHD) and heart failure. CHD
occurs when atherosclerotic plaque builds up inside coronary arteries, a condition that
causes myocardial infarction. Although heart failure can result from the damage caused
by infarcts, a clinically distinct form of heart failure called diabetic cardiomyopathy
(DCM) is characterized by ventricular dilation, myocyte hypertrophy, interstitial fibrosis
and decreased diastolic and/or systolic function that occurs in the absence of underlying
atherosclerotic disease 2-4.

1

In addition to macrovascular complications, diabetic individuals have an increased
prevalence in microvascular complications, such as diabetic retinopathy, which is the
leading cause of blindness (NEI Diabetic Retinopathy, 2010), and diabetic neuropathy,
which accounts for 60% of non-traumatic lower-limb amputations in American adults
(CDC National Diabetes Statistics Report, 2014). Diabetes is also the primary cause of
kidney failure accounting for 44% of new cases (CDC National Diabetes Statistics
Report, 2014). In addition to vascular diseases, people with diabetes are also at a
higher risk for some cancers 5.

Currently, obesity and diabetes are linked to more deaths worldwide than malnutrition
(WHO Diabetes fact sheet, 2016). In 2016, 1.5 million deaths were directly caused by
diabetes, which is the seventh leading cause of death overall (CDC At a Glance Fact
Sheets 2016). Given the high prevalence of obesity and diabetes, the medical costs of
treating the disease and its associated complications have become enormous. It is
estimated that the cost of diabetes care in 2015 alone worldwide was $1.31 trillion USD
6

. A greater understanding the pathogenesis of this disease is essential to decrease

morbidity and mortality and to reduce this growing socioeconomic burden worldwide.

1.2 Systemic metabolic abnormalities in diabetes
As the primary source of the body’s energy, blood glucose levels are tightly regulated to
keep the body in homeostasis. When blood glucose levels are low, pancreatic α-cells
secrete glucagon that converts glycogen into glucose in order to raise blood glucose
levels. Meanwhile, when glucose levels are high, pancreatic β-cells release insulin,
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which signals to cells to take up glucose from blood through the GLUT4 transporter and
to liver and muscle cells to store glucose as glycogen, both of which lower blood
glucose levels. Inadequate insulin action and hyperglycemia is a hallmark of diabetes.
In type 1 diabetes patients, the immune system destroys β-cells, preventing the
pancreas from producing insulin. It is thought to arise from genetic factors and
environmental triggers. However, type 1 diabetes accounts for only 5-10% of all
diabetes cases 7. By contrast, in type 2 diabetes, the pancreas produces insulin, but
tissues in the body become resistant to the actions of the hormone. The inability of
insulin to signal to tissues to take up blood glucose leads to hyperglycemia 8. With
obesity on the rise, type 2 diabetes cases have also increased, with the number of
Americans diagnosed with diabetes increasing fourfold from 1980 through 2014 (5.5
million to 22.0 million) (CDC Diagnosed Diabetes, 2015). Prolonged exposure of
hyperglycemia has been linked to the pathogenesis of complications in both type 1 and
type 2 diabetes, including heart disease, retinopathy and glomerulopathy 9-11.

Large multicenter studies that have tested the ability of tight glycemic control for the
prevention of complications have provided evidence for efficacy in preventing some, but
not all diabetic complications. For example, the DCCT/EDIC trial demonstrated that tight
glycemic control in patients with type 1 diabetes reduced the incidence and severity of
macrovascular and microvascular disease 12. However, in the ACCORD trial, treating
hyperglycemia alone in type 2 diabetes was sufficient to decrease microvascular
complications, but did not have a beneficial effect on macrovascular complications such
as CHD 13. These findings and similar observations in other studies of type 2 diabetes

3

suggested that other associated metabolic disturbances in diabetes may contribute
importantly to complications. For example, in addition to hyperglycemia, patients with
type 2 diabetes often have high circulating triglycerides and free fatty acids (FFA) 14-16.
Hypertriglyceridemia is linked to the incidence and severity of complications, including
neuropathy, retinopathy, non-alcoholic steatohepatitis, heart failure 17-20.

1.3 Lipotoxicity
FFAs and their metabolites are crucial as an energy source, as components of cellular
membranes, and as signaling molecules in many physiological processes. Besides
exogenous sources of FFA in the diet, lipogenic tissues can generate lipids de novo
from excess carbohydrates 21. In conditions of nutritional excess, FFAs are metabolized
to triacylglycerides (TAGs) and stored in neutral lipid droplets in adipose depots. During
nutritional deprivation or sympathetic stimulation, TAGs are hydrolyzed into glycerol and
FFAs, which are released into the bloodstream for distribution of this energy source to
peripheral tissues. The liver also produces FFA and triglycerides, which are secreted
into the circulation as lipoproteins. The hormone insulin negatively regulates lipolysis in
adipose tissue and de novo lipogenesis in the liver. In the setting of insulin resistance,
levels of lipids in the blood stream are high and can further contribute to insulin
resistance in tissues such as skeletal muscle 22-24. Hyperlipidemia may also reflect the
finite capacity for expansion of adipose tissue stores of triglyceride in obesity.

Hyperlipidemia causes increased delivery of FFA and triglycerides to non-adipose
tissues. These tissues have some capacity to metabolize or store FFA as triglyceride in
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ectopic lipid droplets. Studies of cultured cells and animal models suggest that this initial
storage of excess lipid as triglyceride is protective 25-28. However, this capacity for
triglyceride storage in non-adipose tissues is limited. Ultimately, FFA that fail to be
sequestered in triglyceride droplets or that are released from TAG hydrolysis can lead to
cell dysfunction and eventually cell death, a process termed lipotoxicity.

Hyperlipidemia also induces generation of reactive oxygen species (ROS). ROS are
highly reactive molecules with an unpaired electron that are produced during normal
cellular metabolism. One source of endogenous ROS is the electron transport chain
(ETC) in the mitochondria. As electrons are shuttled through the ETC, incomplete oneelectron reduction of oxygen can occur, generating superoxide (O2-), instead of
reduction of oxygen to water. In addition, there are several enzymatic pathways that
produce ROS

29

. For example, nicotinamide adenine dinucleotide phosphate oxidase

(NOX) is an oligomeric protein that can generate O2-

30

. Besides the NOX family, other

enzymes that produce ROS include myeloperoxidase, which is expressed in neutrophils
and produces hypochlorous acid; xanthine-oxidase, which catalyzes the oxidation of
xanthine or hypoxanthine into uric acid; and nitric oxide synthase, which synthesizes
nitric oxide required for vascular tone, neurotransmission and inflammation

29

. Cells

express several ROS scavenging enzymes, such as catalase and glutathione
peroxidases, and proteins with redox active centers that protect against oxidative stress
and enable cells to maintain ROS levels at relatively low levels during homeostatic
conditions. Nonetheless, certain stresses, such as hyperlipidemia, trigger an increase in
ROS production that exceeds the cell’s antioxidant capacity. When this occurs, high
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levels of ROS can damage DNA, post-translationally modify proteins in ways that alter
their function, and lead to lipid peroxidation

29

. For example, excess free fatty acids,

present in metabolic diseases such as type 2 diabetes, produce high levels of ROS
through activation of NOX, through membrane remodeling, and through prolonged ER
stress that ultimately lead to cell dysfunction and cell death 31-34.

The proper function of the endoplasmic reticulum (ER) is necessary for lipid and protein
metabolism under homeostatic conditions. Mutant proteins disrupt protein folding in the
ER, leading to a halt in protein translation, degradation of misfolded proteins, and
activation of signal pathways that increase the production of chaperones involved in
protein folding. If the ER stress is not resolved, this triggers the activation of proapoptotic genes and activation of NOX resulting in oxidative stress

35,36

. Lipids also

cause ER stress. As the major site for synthesis of lipids that constitute biological
membranes, the ER plays an important role in membrane lipid homeostasis. Treating
cells with pathophysiological levels of saturated fatty acid palmitate, but not general
oxidative stress-inducer H2O2, leads to a change in ER membrane composition, thus
compromising ER structure and integrity

31

. The resulting ER and oxidative stress lead

to cellular dysfunction and ultimately, cell death

31,37

. However similar concentrations of

unsaturated long-chain FFAs are well tolerated. Studies have shown that co-treating
cells with saturated and unsaturated long-chain FFAs rescues cells from lipotoxicity
31,38

. These observations have been linked to the greater capacity of cells to store

unsaturated FFA as triglyceride and the ability of of unsaturated FFA to enhance
palmitate incorporation into triglyceride stores 26.
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On a systemic level, prolonged hyperlipidemia has been associated with dysfunction of
many organs. In diabetes, non-alcoholic steatohepatitis 39, glomerulopathy 40, and
cardiomyopathy 41 are associated with ectopic lipid accumulation in these non-adipose
tissues. In patients with congenital lipodystrophies, diminished or absent adipose tissue
leads to ineffective FFA storage and hyperlipidemia that is associated with profound
non-alcoholic steatohepatitis and systemic insulin resistance 42. Although strategies to
decrease serum lipid levels through behaviorial interventions, such as exercise and
improved diets, or by inhibiting de novo lipogenesis can be efficacious, strategies to
prevent lipotoxicity are limited by our incomplete knowledge of the mechanisms
underlying FFA-induced cellular injury.

1.4 Rpl13a snoRNAs mediate cellular response to metabolic
and oxidative stresses
In order to identify novel regulators of the cellular response to lipid overload, the
Schaffer lab has used a cell culture model of lipotoxicity in which non-adipose cells are
grown in media supplemented with pathophysiological levels of the saturated fatty acid
palmitate. Under these conditions, fibroblasts, hepatocytes, cardiomyoblasts, and
endothelial cells develop ER and oxidative stress and ultimately die over the course of
24 to 48 hours. The Schaffer lab used this model to perform a loss-of-function genetic
screen using the ROSABgeo promoter trap.

The integrated ROSABgeo provirus

contains B-galactosidase-neomycin phosphotransferase fusion cassette with a strong
polyadenylation sequences, but lacks its own promoter. Therefore, the ROSABgeo
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transcript is only expressed if it integrates downstream of an actively transcribed RNA
polymerase II promoter. In this case, the neomycin phosphotransferase activity allows
the mutant to survive neomycin selection, and because of the strong polyadenylation
sequence, the endogenous gene at the site of the integration is no longer expressed.
The genetic screen was performed in Chinese hamster ovary (CHO) cells, and mutants
with single promoter trap integrations were selected for growth over 48 hours in the
presence of lipotoxic levels of palmitate 31,43-46.

The locus encoding ribosomal protein L13a (Rpl13a) was identified as the site of
mutation in one of these mutant cell lines and is necessary for the production of
oxidative stress and cell death in response to lipotoxic stress 45. The eight exons in this
locus encode the Rpl13a protein, a constituent of the large ribosomal subunit. This
locus also contains four intronic box C/D small nucleolar RNAs (snoRNAs)—U32a, U33,
U34, and U35a—that are produced from the intron lariats generated during splicing of
the

Rpl13a

pre-mRNA.

Through

complementation

and

directed

knockdown

experiments, the Schaffer lab showed that loss of the intronic Rpl13a snoRNAs, rather
than the Rpl13a protein, were responsible for palmitate resistance in the mutant cell
line. Furthermore, while the Rpl13a snoRNAs are enriched in the nucleus of wild type
cells under basal conditions, they are also detected in the cytoplasm and they rapidly
accumulate in the cytosol in response to lipotoxicity and general inducers of oxidative
stress

44,45,47

. Another mutant isolated from the screen had a disruption in the SmD

locus, a core component of the spliceosome that was shown to be necessary for the
correct processing of snoRNAs from intron lariats
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46

. Intriguingly, haploinsufficiency of

the Rpl13a snoRNAs is sufficient to confer protection from lipotoxicity, but does not alter
the 2’-O-methylation of predicted rRNA targets

45

. Together, these experiments suggest

a potential non-canonical role for the Rpl13a snoRNAs outside of the nucleus in the
cellular response to metabolic stress.

1.5 Small nucleolar RNAs
The Rpl13a snoRNAs are members of a broader class of short noncoding RNAs that
range from 60-200 nucleotides long. Most mammalian snoRNAs, including the Rpl13a
snoRNAs, are encoded within introns, are processed out of intron lariats during splicing,
and lack a 5’ cap structure. There is a small subset of snoRNAs that are independently
transcribed by RNA polymerase II that includes U3, U8 and U13, and in their mature
form contain an m3G cap

48

. SnoRNAs are categorized as belonging to the box C/D or

box H/ACA class based on conserved sequence motifs. Both classes of snoRNAs
complete their maturation to functional ribonucleoproteins (RNPs) with a core set of
proteins in Cajal bodies and then localize within the nucleolus.

Most snoRNAs are known to function in the covalent modification of other noncoding
RNAs within the nucleolus. Specifically, box C/D snoRNAs complex with the
methyltransferase fibrillarin and guide 2’-O-methylation of ribosomal RNAs (rRNA),
while box H/ACA snoRNAs complex with the pseudouridine synthase dyskerin and
guide pseudouridylation of rRNAs. Both classes of snoRNAs contain short (10-20
nucleotides for box C/D snoRNAs) antisense elements that are complementary to the
sequence of their target RNAs, and serve as zipcodes to target the mature snoRNPs to

9

bind specific sites of modification on the target RNAs. SnoRNAs that stay and function
within the Cajal bodies are called small Cajal body-specific RNA (scaRNA). ScaRNAs
guide 2’-O-methylation and pseudouridylation on small nuclear RNAs (snRNA)

49

. A

number of snoRNAs are considered orphans on the basis that there is no known target
rRNA

50

. In some instances, snoRNA-directed modifications have been shown to be

necessary for proper ribosome and spliceosome function
rRNA species

55

, or for stability of rRNA

56

51-54

, for processing of pre-

. In addition, there is a growing body of

evidence of snoRNA roles outside of rRNA or snRNA modification, including roles in
modification of pre-mRNAs to direct splicing

57

, regulation of RNA editing

58

, miRNA-like

post-transcriptional regulation 59, and pseudouridylation of mRNA targets 60.

Recent studies also provide evidence for novel functions of snoRNAs in disease states.
In a knock-in mouse model with loss-of-function of the Rpl13a snoRNAs generated by
the Schaffer lab, cells and tissues from the knock-in mouse have lower basal ROS tone
and are resistant to metabolic stress and diabetogenic stimuli

61

. This suggests that

Rpl13a snoRNAs could play a role in metabolic diseases. SnoRNAs have also been
implicated in cancer. Box C/D snoRNA U50 is downregulated in prostate cancer and
breast cancer

62

, while box H/ACA snoRNA SNORA42 is overexpressed in non-small-

cell lung cancer

63

. Furthermore, deletions that included loss of box C/D snoRNAs

SNORD14D, SNORD43, U34 and U35a, suppressed leukaemogenesis
these findings implicate snoRNAs in disease pathogenesis.
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64

. Together,

The finding that Rpl13a snoRNAs are present in the cytosol under homeostatic
conditions and the observation that metabolic stress conditions regulate the cytosolic
levels of these and other snoRNAs suggests these non-coding RNAs could have
functions outside the nucleus. Since knockdown and loss-of function approaches to
study the functions of snoRNAs affect the nuclear and cytosolic pools of the targeted
species, these approaches have limited ability to identify roles of snoRNAs in specific
subcellular compartments. In order to elucidate potential functions of snoRNAs in the
cytosol, it would be ideal to disrupt trafficking of these non-coding RNAs out of the
nucleus. However, mechanisms that regulate movement of snoRNAs between the
nucleus and cytoplasm are poorly characterized. In the present study, we demonstrate
that the dynamic localization of snoRNAs is regulated by superoxide through DOXinduced activation of enzyme NOX4D.

1.6 RNA transporters
Most RNAs exit the nucleus complexed as RNPs through the nuclear pore complexes
(NPC) that are made up of nucleoporin proteins. Members of the nuclear export factor
(NXF) family play important roles in the export of RNA by physically interacting with the
nucleoporins to facilitate export. The NXF family is comprised of five functional
members NXF1, NXF2, NXF3, NXF5 and NXF7. NXF family members have been
identified based on similarity of sequence and domain architecture. Most include an
amino terminal RNA binding interaction domain, a p15/NXFt-heterodimerization domain
that recruits NXF adaptor p15 necessary for nuclear transport, and a carboxyl terminal
ubiquitin associated domain involved in NPC binding 65,66.
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NXF family members have been shown to function in the transport of specific classes of
RNAs. For example, Nuclear export factor 1 (NXF1) is considered the bulk mRNA
transporter. NXF1 operates with several other proteins, including ALY and a cap-binding
complex, which help target its mRNA cargo, and with p15, which helps the NXF1-mRNA
complex physically interact with nucleoporins to exit the nucleus through the NPC.
Unlike other RNA transport, NXF1-mediated mRNA export is RanGTP independent
indicating that directionality of transport is established through a different mechanism 67.
NXF2, NXF3 and NXF5 have also been shown to function in the nuclear export of
mRNAs, whereas NXF7 has been proposed to function in the cytoplasmic trafficking of
mRNAs 68-73.

Other classes of transporters have been shown to be involved in nucleocytoplasmic
transport of small RNA species. The transport of tRNAs is mediated through exportin-t
and transport of miRNAs is mediated through exportin-5. Both exportins directly bind
their target RNA in an RanGTP-dependent manner. The exportin-RNA-RanGTP
complex is exported through the NPC to the cytoplasm where RanGTP is hydrolyzed,
thus releasing its cargo in the cytoplasm. Export receptor CRM1 is required for snRNA
export and is also RanGTP-dependent. However, unlike tRNA and miRNA export, in
which their specific export receptors bind directly to their target RNA, CRM1 requires
adaptor protein PHAX and a cap binding complex to bind to its RNA cargo 67.
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SnoRNAs have long been thought to complete their biogenesis and function within the
nucleus. In eukaryotic cells, most snoRNAs are encoded within pre-mRNA introns, while
some snoRNAs are independently transcribed. Both types of snoRNAs are transcribed
in the nucleus. SnoRNP proteins, like fibrillarin and dyskerin, bind immature presnoRNAs while they are trimmed by exonucleases in the nucleoplasm. The snoRNPs
are then trafficked to the Cajal bodies for maturation. Mature snoRNPs either stay within
the Cajal body, as is the case for scaRNAs, or traffic to the nucleolus where they guide
the modification of newly synthesized rRNAs

51,54,74

. Nuclear export receptors PHAX

and CRM1 are necessary to sequentially transport independently-transcribed snoRNA
U3 from the Cajal body to the nucleolus for correct snoRNP maturation

75

. Although

PHAX and CRM1 can also function as export receptors, there is not evidence that they
are involved in nucleocytoplasmic transport of U3 or other snoRNAs.

Nonetheless, several studies suggest that cells have endogenous mechanisms for
transport of independently transcribed and capped snoRNAs between the nucleus and
cytoplasm. Xenopus oocytes provide evidence for an endogenous pathway that
transports capped U3 from the cytoplasm to the nucleus following microinjection of in
vitro transcribed U3

75

. Moreover, U8 snoRNA associates with the import factor

snurportin 1 in mammalian cells, and knockdown of this transport adaptor is associated
with increased cytosolic U8

76

. Whether snurportin 1 serves a broader role in transport

of the overall class of snoRNAs, and whether other transport proteins function to
regulate the distribution of snoRNAs between the nucleus and cytoplasm is not known.
In particular, it is uncertain whether these mechanisms apply to intronic, uncapped
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snoRNA transport. In the present study, we identified nuclear export factor (NXF3) as a
snoRNA nucleocytoplasmic transporter that can be regulated by cyclic AMP and ROS
levels.
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CHAPTER TWO:
Metabolic stress regulates snoRNA trafficking
2.1 INTRODUCTION
The four intronic box C/D snoRNAs from the Rpl13a locus are critical mediators of
lipotoxicity

45

. Although snoRNAs are thought to reside and function exclusively in the

nucleolus, the Rpl13a snoRNAs rapidly accumulate in the cytosol when cells are
exposed to pathophysiological levels of palmitate, a known inducer of oxidative stress.
In addition, oxidative stress resulting from hydrogen peroxide treatment also causes
these snoRNAs to accumulate in the cytosol

44,45

. These observations suggested that

ROS is an important regulator of snoRNA localization.

Reactive oxygen species (ROS) are highly reactive molecules with unpaired electrons
that are produced during normal cellular metabolism. A major source of endogenous
ROS is the electron transport chain in the mitochondria
enzymatic pathways that produce ROS

78

77

. In addition, there are several

. Nicotinamide adenine dinucleotide

phosphate oxidase (NOX) is an oligomeric protein that can generate superoxide. There
are seven isoforms of the NOX catalytic subunit, each characterized by a cytoplasmic
N-terminus, six transmembrane domains, and a long cytosolic C-terminal tail. All seven
isoforms, except for NOX5, require the transmembrane protein p22phox for stability and
activation

30,79

. However, the isoforms differ with respect to tissue distribution and

subcellular localization. NOX2 is considered the prototype NOX. It is localized in the
membranes of phagosomes and highly expressed in phagocyte-specific tissues, where
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its ROS production contributes to the elimination of microbes

30

. On the other hand,

NOX4 is known to localize in the mitochondria in the heart, where it is constitutively
active

30,80

. There are four splice variants of NOX4 (NOX4B, NOX4C, NOX4D and

NOX4E) that may have different functions in ROS-related signaling. Specifically, splice
variant NOX4D lacks the transmembrane domain and is found to localize within the
nucleus

81,82

, raising the possibility that it could be involved in generating ROS in the

vicinity of snoRNAs.

Although snoRNAs have been established as guides to 2’-O-methylation and
pseudouridylation of other small noncoding RNAs within the nucleus, their role in the
cytosol and regulation of their localization outside of the nucleus have previously not
been investigated. Our goal was to investigate the mechanisms underlying the cytosolic
localization of Rpl13a snoRNAs under metabolic stress conditions and to determine
whether the cytosolic localization applies specifically to the Rpl13a snoRNAs or to the
snoRNAs as a class.

2.2 RESULTS
2.2.1 Doxorubicin treatment increases cytosolic Rpl13a snoRNA levels in
cardiomyoblasts
Our lab has previously demonstrated that the accumulation of cytosolic Rpl13a
snoRNAs begin to accumulate in the cytosol after treatment with 6-8 h of palmitate or 35 h of hydrogen peroxide, both of which induce high levels of cellular ROS 44,45. Another
potent inducer of ROS is the chemotherapy drug doxouribicin (DOX)
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83,84

. We treated

H9c2 rat cardiomyoblasts with 20 µM DOX for 1 h, isolated the cytosolic and nuclear
fraction of cells using sequential detergent extraction, and used RT-qPCR to measure
levels of the Rpl13a snoRNAs relative to Rplp0. As expected, prior to DOX treatment,
U32a, U33 and U34 levels were 400-500X more abundant in the nuclear fraction than
the cytosolic fraction (Figure 2.1A). Cytosolic proteins (HSP90, α-tubulin) were enriched
in the cytosolic fraction while nuclear proteins (nucleophosmin and histone H3) were
enriched in the nuclear fraction (Figure 2.1B). After DOX treatment, we detected 12-, 4, and 8-fold increases in the cytosolic abundance of U32a, U33, and U34 (Figure 2.1A).
The levels of total and nuclear Rpl13a snoRNAs were not significantly increased after
DOX treatment and the nuclear proteins did not appear in the cytosolic fraction after
DOX treatment. This suggests that the observed increase in the Rpl13a snoRNAs is not
due to any decrease in nuclear integrity or overall increase in total snoRNA levels
(Figure 2.1A-C).

2.2.2 Superoxide is necessary for cytosolic Rpl13a snoRNA accumulation during
doxorubicin treatment
DOX has been shown to induce superoxide through the NOX enzymes

85,86

. To

determine whether the localization of the Rpl13a snoRNAs during DOX treatment was
dependent on superoxide, we tested whether NOX inhibitor DPI or the superoxide
scavenger Mn(III)TMPyP (MnT) could inhibit the cytosolic accumulation of the Rpl13a
snoRNAs. Co-treatment of H9c2 rat cardiomyoblasts with DPI or MnT, blunted the
DOX-induced accumulation of cytosolic Rpl13a snoRNAs (Figure 2.2A). Moreover,
treating H9c2 rat cardiomyoblasts with DPI alone resulted in lower levels of cytosolic
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snoRNAs (Figure 2.2B). Together, these results suggest the production of superoxide
by a NOX enzyme is required for Rpl13a snoRNA accumulation in the cytosol both after
DOX treatment and under normal homeostatic conditions. We next tested whether the
inhibitory effects of DPI and MnT on cytosolic snoRNA accumulation simply reflected
inhibition of DOX-induced nucleolar stress.

We performed immunofluorescence

staining of the nucleolar protein nucleophosmin (NPM) to assess nucelolar integrity
during DPI, MnT and DOX treatments

87

. Nucleolar punctae, present under basal

conditions, were lost after DOX treatment, consistent with nucleolar stress, but NPM
staining remained localized within the nucleus (Figure 2.2C). Thus, although MnT and
DPI blunted the accumulation of cytosolic Rpl13a snoRNAs after DOX treatment, the
drugs had no effect on the DOX-induced nucleolar stress, suggesting that the nucleolar
dissolution is not dependent on superoxide or NOX activity. Together, our results are
consistent with a model in which Rpl13a snoRNA accumulation in the cytosol is
dependent on ROS and is not the result of generalized nucleolar stress.

2.2.3 NADPH oxidase 4D mediates cytosolic Rpl13a snoRNA accumulation in
response to doxorubicin treatment
The ability of DPI and MnT to inhibit cytosolic snoRNA accumulation after DOX
suggested a mechanism involving the NOX enzyme family. In cardiomyoblasts, NOX4
activity is dependent on the p22 subunit, and one of its four splice variants, NOX4D,
localizes in the nucleus and nucleolus

82,88

. Given its localization, we hypothesized that

NOX4D could generate nuclear ROS to impact snoRNA localization. Given the gene
structure of NOX4D, it was not possible to design an siRNA specific to NOX4D (Figure
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2.3). We used two independent siRNAs against the following targets: NOX4A at exons 3
or 5 (siRNA NOX4A), both NOX4A and NOX4D isoforms at exons 12-13 or 14 (siRNA
NOX4AD), or the regulatory p22 subunit. Following transfection of cardiomyoblasts,
total mRNA levels of p22 were significantly knocked down by two independent siRNAs
(Figure 2.4A). Total mRNA levels of NOX4A were significantly knocked down by all
NOX4A and NOX4AD siRNAs (Figure 2.4B). Total mRNA levels of NOX4D were
significantly knocked down only by NOX4AD siRNAs (Figure 2.4C). Knockdown of
these targets was not affected by DOX treatment (Figures 2.4A-C). SiRNA against
NOX4AD and p22 recapitulated the effects of MnT and DPI, significantly blunting
cytosolic accumulation of Rpl13a snoRNAs after DOX treatment, whereas siRNA
against NOX4A only had no significant effect (Figures 2.4D). These data implicate
NOX4D as a mediator of cytosolic snoRNA accumulation in response to DOX treatment.
Similar to DPI and MnT treatment, none of the siRNA knockdowns inhibited nucleolar
stress induced by DOX (Figure 2.4E).

2.2.4 SnoRNAs are dynamically regulated in the cytoplasm
To determine whether ROS-regulated accumulation of snoRNAs in the cytosol is
specific for Rpl13a snoRNAs or relevant to snoRNAs as a class of noncoding RNAs, we
used RNA sequencing to analyze H9c2 rat cardiomyoblasts following treatment with
DOX with or without DPI. We prepared small RNA-sequencing libraries from cytosolic
RNA of 35-350 nucleotides in order to capture snoRNAs while minimizing overlap with
miRNAs. For each condition, we generated 3 independent libraries that were
sequenced on an Illumina HiSeq 2500. Aligned reads were annotated using Ensembl
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Rat Build 369, which specifies 560 noncoding RNAs (ncRNA), including 215
sno/scaRNAs. Total raw reads per condition were similar, as were the number of reads
aligned to the genome and >99% of annotated reads corresponded to small ncRNA
genes (Table 2.5A). DOX treatment resulted in a significant increase in both the
number and proportion of annotated reads that mapped to box C/D snoRNAs (Table
2.5A and Figure 2.5A). Significantly fewer box C/D snoRNAs were recovered with DPI
treatment, similar to our findings for the Rpl13a snoRNAs. Cytoplasmic box H/ACA
snoRNAs and scaRNAs followed the same pattern as box C/D snoRNAs, but did not
reach statistical significance (Figure 2.5A).

In our RNA-sequencing data, changes in the cytosolic abundance for U32a, U33 and
U34 after DOX and/or DPI treatment were similar to those found by RT-qPCR (Figure
2.5B, lower). The RNA-seq method was also able to detect a 3-fold increase in
cytosolic U35a after DOX treatment, which was not detected by RT-qPCR. This may be
due to the superior sensitivity of the RNA-seq method, as U35a is 100-fold less
abundant than U34, the most abundant Rpl13a snoRNA (Figure 2.5B, upper).

Overall, we detected 256 of 560 annotated small ncRNA, including 94 of the 119
annotated box C/D snoRNAs, in the cytoplasm (Figure 2.5C). We determined
differential representation in the cytoplasm after DOX treatment using normalized read
counts and parameters of >2-fold change with false discover rate <0.05. The 105 genes
that passed these criteria were all sno/scaRNA with increased cytosolic expression after
DOX treatment, 89 of which were box C/D snoRNAs (Figure 2.5C). These significantly
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increased box C/D snoRNAs account for 95% of the detectable cytoplasmic box C/D
snoRNAs, suggesting a strong class effect. Although much fewer, annotated box H/ACA
snoRNAs and scaRNA were detected in the cytosol, and more than half also showed
significant increases in the cytosol after DOX treatment (Figure 2.5C). Together, this
RNA-seq data provides evidence that DOX can induce the cytosolic accumulation of a
broad range of snoRNAs through a NOX-dependent mechanism.

2.3 CONCLUSIONS
Through RT-qPCR and RNA-seq analyses, we have demonstrated that snoRNAs as a
class are not exclusively localized to the nucleus. While the majority of the snoRNAs are
localized within the nucleus under basal, homeostatic conditions, snoRNAs are
detectable in the cytosol, where their cytosolic abundance is dynamically regulated by
oxidative stress. Our results support a model in which DOX treatment induces NOX4Ddependent nuclear superoxide, which leads to snoRNA accumulation in the cytosol
(Figure 2.6).
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2.4 FIGURES

Figure 2.1 Doxorubicin treatment increases cytosolic Rpl13a snoRNA levels in
cardiomyoblasts. H9c2 cardiomyoblasts were treated with vehicle alone (ctrl) or 20 µM
DOX for 1 h. A-B. Cytosolic and nuclear extracts were prepared from ctrl and DOX
treated cells by sequential detergent extraction. Cytosolic and nuclear RNA were
quantified by RT-qPCR with normalization to the control transcript Rplp0. Error bars
show 95% confidence interval for n = 3 independent experiments (A). Fractions were
analyzed by western blot for cytosolic protein markers (HSP90, α-tubulin) and nuclear
protein markers (NPM, histone H3) (B). C. Total RNA was assayed by RT-qPCR with
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normalization to the control transcript Rplp0. Error bars show 95% confidence interval
for n = 3 independent experiments.
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Figure 2.2 Superoxide is necessary for cytosolic Rpl13a snoRNA accumulation
during doxorubicin treatment. A. Cells were treated for 1 h with vehicle alone (ctrl) or
combinations of 20 µM DOX, 500 nM DPI, and 200 µM MnT as shown. Cytosolic RNA
was isolated by digitonin extraction and snoRNAs were analyzed by RT-qPCR relative
to Rplp0. Error bars show 95% confidence interval for n = 3 independent experiments.
B. Cells were treated with DPI or MnT alone. Cytosolic RNA was isolated by digitonin
extraction and snoRNAs were analyzed by RT-qPCR relative Rplp0. Error bars show
95% confidence interval for n = 3 independent experiments. C. Cells were analyzed by
immunofluorescence microscopy for detection of NPM under ctrl and 1 h DOX-treated
conditions and also in the presence of DPI or MnT. Micrographs show representative
fields. Scale bar, 200 µM. *, p < 0.05 versus cyto/ctrl; &, p < 0.05 versus nuclear/ctrl; #,
p < 0.05 versus DOX alone.
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Figure 2.3 Exonic structure of NOX4A and alternatively spliced nuclear form
NOX4D. Localization of siRNAs that target NOX4A only (exons 3 and 5) or both NOX4A
and NOX4D (exons 12-13 and 14).
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Figure 2.4 NADPH oxidase 4D mediates cytosolic accumulation of Rpl13a
snoRNAs in response to doxorubicin treatment. A-D. H9c2 cardiomyoblasts were
transfected for 24 h with siRNA targeting transcripts as shown: control (ctrl), p22,
NOX4A, or NOX4AD. Cells were then treated with 20 µM DOX for 1 h where indicated.
RNAs were quantified by RT-qPCR relative to Rplp0. Error bars show 95% confidence
interval for n = 3 independent experiments. Total RNA was quantified for target
knockdown with and without DOX treatment (A-C). Cytosolic snoRNAs were quantified
after specified siRNA knockdown and DOX treatment (D). Cells were treated as above
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and analyzed by immunofluorescence microscopy for localization of nucleolar marker
NPM. Micrographs show representative fields (E). Scale bar, 200 µM. *, p < 0.05 versus
ctrl; #, p < 0.05 versus ctrl/DOX; &, p < 0.05 versus NOX4A/DOX.
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Figure 2.5 SnoRNAs are dynamically regulated in the cytoplasm. H9c2
cardiomyoblasts were treated with 20 µM DOX in the absence or presence of 500nM
DPI for 1 h. A. Normalized RNA-seq read counts for annotated cytosolic small ncRNA
classes. Annotated reads were normalized as reads per million raw reads (RpM) and
shown as the mean + standard error (SE) for n = 3 independent experiments . B. RNAseq expression data for the Rpl13a snoRNAs in response to treatment with DPI, DOX,
or DPI/DOX. Read data are shown as RpM aligned reads to demonstrate the relative
abundance of different Rpl13a snoRNA species (upper). These values were then further
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normalized to the control sample and graphed to show relative expression by treatment
(lower). Mean (+SE) for n = 3 independent experiments. C. The number of genes
annotated for the rat genome (Ensembl ncRNA), number of genes detected
experimentally in the cytoplasm by RNA-seq, and number of genes detected in the
cytoplasm and up-regulated by DOX versus ctrl are shown by ncRNA subclass. *, p <
0.05 for treatment versus ctrl; #, p < 0.05 for DPI/DOX versus DOX alone.
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Table 2.5A Cytoplasmic RNA-seq reads (total per condition)
ctrl

DPI

dox

DPI/dox

Raw

15,777,864

14,321,914

16,038,254

16,539,780

Aligned

15,297,385

13,838,068

15,282,623

15,844,700

Annotated

11,026,233

9,976,388

11,264,042

11,475,445

Annotated ncRNA

10,972,911

9,931,129

11,201,347

11,418,071

sn/sno/scaRNA

453,102

285,808

2,472,756

1,709,804

miRNA

265,594

259,443

305,213

266,277

rRNA (5S + 5.8S)

10,243,718

9,376,317

8,413,350

9,431,538

misc

8,746

8,247

8,236

8,667

snRNA

5,275

4,959

6,105

4,469

scaRNA

1,828

1,221

13,340

8,989

C/D snoRNA

443,462

278,003

2,439,357

1,685,855

H/ACA snoRNA

2,537

1,625

13,954

10,491
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Figure 2.6 Model for cytoplasmic snoRNA regulation. Doxorubicin (DOX) treatment
induces high levels of superoxide through the activation of NOX4D enzyme and its
regulatory subunit p22. The DOX-induced oxidative stress leads snoRNAs as a class to
accumulate in the cytosol. NOX inhibitor DPI and superoxide scavenger MnT inhibit the
ability of DOX to increase levels of superoxide and thus blunt the accumulation of
snoRNAs in the cytoplasm.
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CHAPTER THREE:
NXF3 functions as a nucleocytoplasmic snoRNA
transporter
3.1 INTRODUCTION
Following transcription, snoRNAs that are processed from the introns of pre-mRNA or
that are generated from independently transcribed units, first move to Cajal bodies
where they assemble in to mature snoRNPs, and subsequently to the nucleolus where
they encounter nascent rRNA substrates. While Rpl13a snoRNAs localize primarily in
the nucleus, these and other intronic snoRNAs are readily detected in the cytoplasm
under homeostatic conditions

76,89

, and they accumulate outside the nucleus during

lipotoxic conditions, oxidative stress, and serum starvation

45,47,90

. However, a

nucleocytoplasmic trafficking pathway has not yet been identified for the class of
snoRNAs.

Nuclear export factor 3 (NXF3) was identified through an shRNA loss-of-function
genetic screen in human umbilical endothelial cells (HUVECs) to identify genes required
for the cytotoxic response to metabolic stress. Based on its sequence and functional
domain similarities, NXF3 is considered to be a member of the nuclear export factor
(NXF) family, which includes known mRNA exporter, nuclear export factor 1 (NXF1).
However, NXF3 lacks the carboxyl terminal domain, ubiquitin-associated domain (UBA),
which is involved in nuclear pore binding, and is required for nuclear export function of
other family members

73

. Nonetheless, previous studies have demonstrated that like

other family members, NXF3 shuttles between the nucleus and cytoplasm. A leucine
32

rich nuclear export sequence (NES) was identified within NXF3 that recruits CRM1, thus
allowing NXF3 to export cargo through the nucleus

73

, but no nuclear import sequence

has been defined in the NXF3 sequence. In cells transfected with an HA-tagged form of
NXF3 (HA-NXF3), Yang et al isolated poly(A) RNA/protein complexes using oligo dT
cellulose. They demonstrated that there was a specific interaction between poly(A) RNA
and HA-NXF3. This data implicated NXF3 in the nuclear export of mRNA. However,
using oligo dT cellulose excludes noncoding RNAs, like snoRNAs, which are not
polyadenylated.

73

. The endogenous cargo for NXF3 remains to be defined, including

determination of whether it can transport other RNA species like noncoding RNAs.
Given that genetic screens implicated both Rpl13a snoRNAs NXF3 in lipotoxic response
pathways, we hypothesized that NXF3 may also serve as a transporter for snoRNAs.

3.2 RESULTS
3.2.1 NXF3 knockdown protects against lipotoxic cell death in endothelial cells
To identify genes critical for the cell death response to lipotoxicity, we performed a
genome-wide loss-of-function shRNA screen in immortalized human umbilical vein
endothelial cells (HUVECs), which are sensitive to lipotoxicity. Cells were transduced
with pools of lentivirus containing shRNAs targeting expressed human genes and a
puromycin selectable marker. HUVECs that survived puromycin selection were then
treated for 48 hours in media supplemented with pathophysiological levels of palmitic
acid to model lipotoxic conditions. Cells containing an shRNA targeting NXF3 had
significantly improved survival compared to cells transduced with a non-targeting,
control shRNA (Fig. 3.1A). The shRNA targeting NXF3 led to a 72% decrease in NXF3
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mRNA levels (Fig. 3.1B) and a 28% decrease in NXF3 protein expression (Fig. 3.1C),
consistent with knockdown of its gene target in these lipotoxicity-sensitive human cells.
Together these observations implicate a critical role for NXF3 in the lipotoxic response
pathway.

3.2.2 NXF3 knockdown endothelial cells have aberrant Rpl13a snoRNA
localization
NXF3 is a member of the NXF family that includes the general mRNA export receptor,
NXF1. While NXF3 can associate with mRNAs
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, other potential cargo such as

noncoding RNAs have not been investigated. Given the important role of Rpl13a
snoRNAs U32a, U22, U34, and U35a in lipotoxic and oxidative stress-induced cell
death, and the observation that these snoRNAs accumulate in the cytoplasm under
metabolic stress conditions

45,47

, we hypothesized that NXF3 knockdown might affect

localization of snoRNAs. We assessed Rpl13a snoRNA localization in cytosolic
fractions of control- and NXF3-shRNA transduced cells by isolating cytosolic and noncytosolic fractions using digitonin extraction. Under normal homeostatic growth
conditions, levels of cytosolic Rpl13a snoRNAs in NXF3 shRNA transduced cells were
significantly increased compared with control shRNA transduced cells, while total levels
of the snoRNAs did not significantly change (Figure 3.2A). Control western blots
demonstrated that both nuclear (nucleophosmin) and cytosolic (HSP90, α-tubulin)
markers segregated as expected in both control and NXF3 shRNA transduced cells
(Figure 3.2B). Following treatment with hydrogen peroxide to induce oxidative stress,
U32a, U33 and U34 snoRNAs accumulate in the cytoplasm of control shRNA

34

transduced HUVEC cells (Figure 3.2C), consistent with prior observations in other cell
types that oxidative stress stimulates cytosolic accumulation of Rpl13a snoRNAs 44,47. In
contrast, hydrogen peroxide did not cause further increase in the cytoplasmic levels of
snoRNAs in NXF3 shRNA transduced cells. Hydrogen peroxide had no detectable
effect on localization of U35a in shRNA transduced HUVEC cells, as has been
observed for this less abundant Rpl13a snoRNA

47

. Elevated cytoplasmic levels of the

snoRNAs under homeostatic conditions in NXF3 shRNA-transduced cells is unlikely to
be the result of increased basal oxidative stress or nucleolar stress, since intracellular
ROS levels as assessed by dihydroethidium staining (Figure 3.2D) and nucleolar
integrity as assessed by nucleophosmin staining (Figure 3.2E) were unchanged
compared to control cells. Our findings that loss-of-function of NXF3 perturbs Rpl13a
snoRNA subcellular localization indicates that NXF3 functions under homeostatic
conditions to maintain the distribution of these non-coding RNAs between the nucleus
and cytoplasm. Although NXF3 has been proposed as an mRNA export factor,
accumulation of Rpl13a snoRNAs in the cytosol in the setting of NXF3 knockdown
implicates an additional role for this protein in nuclear import of these small non-coding
RNAs.

3.2.3

Knockdown

of

NXF3

increases

cytosolic

Rpl13a

snoRNAs

in

cardiomyoblasts
We used transient knockdown to confirm our observations regarding NXF3 loss-offunction in an independent cell type and compared the effects of knockdown of NXF3
and related family member, NXF1 (Figure 3.3A). Compared to control non-targeting
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siRNA, two independent siRNAs directed against NXF3 led to a 93% and 84%
decrease, respectively, in NXF3 mRNA levels in H9c2 rat cardiomyoblasts, but did not
significantly change levels of NXF1 (Figure 3.3B, left graph). Because we found that
commercially available antibodies directed against rodent NXF3 are not specific for this
family member (not shown), and our attempts to generate a specific antibody that
recognizes the rat or murine protein were unsuccessful, extent of knockdown of the
endogenous NXF3 protein could not be confirmed. Nonetheless, knockdown of NXF3
mRNA by each siRNA led to a 50 to 200% increase in cytosolic levels of the Rpl13a
snoRNAs (Figure 3.3B, right graph) without perturbing efficiency of fractionation
(Figure 3.3C). In contrast, siRNA knockdown of NXF1 had no effect on cytosolic levels
of Rpl13a snoRNAs (Figure 3.3 D and E). Thus, accumulation of Rpl13a snoRNAs in
the cytosol can result from either acute or chronic knockdown of NXF3. This effect is
specific for NXF3 and appears consistent across different cell types.

3.2.4 Overexpression of NXF3 decreases cytosolic Rpl13a snoRNAs in
cardiomyoblasts
Our data are consistent with a model in which NXF3 function is required to maintain low
cytoplasmic levels of the Rpl13a snoRNAs. To test whether NXF3 promotes movement
of snoRNAs between the cytosol and nucleus, we overexpressed murine NXF3 by
transiently transfecting NIH 3T3 murine fibroblasts with a GFP-tagged NXF3 construct
(NXF3-GFP). As negative controls, we transfected plasmids expressing GFP alone or
GFP-tagged NXF1 construct (NXF1-GFP) (Figure 3.4A). We consistently observed
more efficient transfection with GFP compared to NXF3-GFP and NXF1-GFP,
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suggesting that endogenous mechanisms serve to restrict the overall expression of
NXF3 and NXF1. Nonetheless, compared to expression of GFP alone, expression of
NXF3-GFP decreased cytosolic levels of the Rpl13a snoRNAs by 16-34% while there
was

no

significant

change

in

cytosolic

Rpl13a

snoRNAs

after

NXF1-GFP

overexpression (Figure 3.4B and C). Additionally, we transiently transfected rat
cardiomyoblasts with a non-tagged construct of NXF3. Comparable decreases in U32,
U33 and U34 were observed between non-tagged and GFP-tagged NXF3 (Figure
3.4D). Together with findings from knockdown of NXF3, our data suggest a model in
which NXF3 promotes movement of snoRNAs from the cytoplasm to the nucleus and
determines the distribution of the snoRNAs between these cellular compartments.

3.2.5 NXF3 and NXF1 associate with snoRNAs
Since NXF3 is a member of a nuclear RNA transporter family and genetic manipulation
of NXF3 impacted Rpl13a snoRNA localization, we hypothesized that NXF3 may serve
as a snoRNA transporter. A corollary of this hypothesis is that NXF3 should physically
interact with the Rpl13a snoRNAs. We transiently transfected H9c2 rat cardiomyoblasts
NXF3-GFP or GFP alone, and NIH 3T3 murine fibroblasts with NXF3-GFP, NXF1-GFP,
or GFP alone and performed immunoprecipitation studies using a GFP antibody, or
non-immune IgG as a control. Antibody directed against GFP efficiently and specifically
pulled down GFP, NXF3-GFP, or NXF1-GFP, while no GFP, NXF3-GFP or NXF1-GFP
was recovered in control IgG immunoprecipitations (Figure 3.5A and B). Real-time
PCR quantification revealed a 7- to 10-fold increase in Rpl13a snoRNA association with
immunoprecipitated

NXF3-GFP

compared
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to

immunoprecipitated

GFP

in

cardiomyoblasts and 10- to 15-fold increase in fibroblasts (Figure 3.6A and B).
Interestingly, real-time PCR quantification revealed NXF1-GFP also associated with the
Rpl13a snoRNAs at similar levels as NXF3-GFP in NIH 3T3 murine fibroblasts.
Although only knockdown and overexpression of NXF3 alered snoRNA localization
(Figures 3.3 and 3.4), our data indicate that both NXF family members are capable of
associating with the Rpl13a snoRNAs.

We used RNA-sequencing to determine whether NXF3 associates only with Rpl13a
snoRNAs or with snoRNAs more broadly. We collected RNA from cell lysates before
immunoprecipitation (input) and RNA from immunoprecipitates (pulldown) of NIH 3T3
murine fibroblasts transfected with NXF3-GFP. Because most snoRNAs lack polyA tails
and do not efficiently prime with random hexamers, they are not well represented in
standard libraries prepared using approaches suitable for mRNAs and larger noncoding RNAs
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. To achieve broad coverage of snoRNAs from both input and pulldown

samples, we size-selected RNAs from 30 to 375 nucleotides, a range that would
exclude most miRNAs and include most snoRNAs. Libraries were prepared using an
Illumina small RNA library preparation kit, sequenced, and aligned to mm9 Refseq
Transcripts. We focused our analyses on the non-rRNA sequences, which accounted
on average for 55% reads in both input and pulldown samples (Table 3.6A). Greater
than 98% of non-rRNA reads in the input and pulldown samples aligned to snoRNAs, as
expected (Table 3.6B). In addition to the Rpl13a snoRNAs, NXF3 pulldown recovered
many other snoRNAs (Table 3.6C), most of which belonged to the box C/D class of
snoRNAs, known to be most abundant

93-95

. Approximately 6% of reads in both input
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and pulldown aligned to box H/ACA snoRNAs. Due to the methods required to capture
snoRNA sequences in library preparation, it was not possible to determine whether
NXF3 specifically enriches for snoRNAs over other classes of RNAs. Nonetheless, lack
of significant enrichment of specific snoRNA species in pulldown relative to input
snoRNAs, indicates that NXF3 broadly associates with this class of small RNAs and
does not have specificity for the Rpl13a snoRNAs or other particular species (Table
3.6C). To validate association with additional box C/D and box H/ACA snoRNAs, we
transfected NIH 3T3 fibroblasts with NXF3-GFP or NXF1-GFP or GFP as control,
immunoprecipitated with antibody to GFP, and performed RT-qPCR on recovered RNA
for abundant snoRNAs for which stem-loop primers were successfully designed. Each
of the snoRNAs tested showed similar enrichment in NXF3-GFP and NXF1-GFP
pulldown over GFP pulldown, with the exception of SNORA52 (Figure 3.6C). Together,
our data indicate that NXF3 and NXF1 are capable of associating with a broad range of
snoRNAs. Nonetheless, gain- and loss-of-function analyses indicate that only NXF3
functions as a snoRNA nucleocytoplasmic transporter.

3.3 CONCLUSIONS
The endogenous substrates for NXF3, a member of a family of RNA transport proteins,
are not well characterized. We show that NXF3 and NXF1 associate with the Rpl13a
snoRNAs, along with many box C/D and box H/ACA snoRNAs. We demonstrate that
gain- and loss-of-function of NXF3, but not NXF1, alters the subcellular distribution of
snoRNAs encoded within the Rpl13a locus. Together, our data are most consistent with
a model in which snoRNAs cycle between the nucleus and cytoplasm and NXF3
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efficiently imports snoRNAs from the cytoplasm to the nucleus, a function that helps to
maintain low levels of snoRNAs in the cytoplasm under normal homeostatic conditions.
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3.4 FIGURES AND TABLES

FIGURE 3.1. Knockdown of NXF3 protects against lipotoxic cell death in
endothelial cells. Human umbilical vein endothelial cells (HUVECs) were transduced
with non-targeting (ctrl) or NXF3-targeting shRNA. A. Viability following 48 h incubation
in media containing 500 µM palmitate. Mean (+ SE) for n = 4. B. RT-qPCR
quantification of NXF3 mRNA relative to Rplp0 (relative units, RU). Mean (+ SE) for n =
3. C. Representative western blot analysis (above) of NXF3 and HSP90 expression or
total protein by Ponceau staining with quantification of mean (+SE) NXF3 expression
relative to HSP90 or total protein from n = 3 experiments. *, p < 0.05; **, p < 0.01 for
NXF3 knockdown vs. ctrl
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FIGURE 3.2. NXF3 knockdown alters Rpl13a snoRNA localization under basal
growth conditions in endothelial cells. HUVECs were transduced with ctrl or NXF3targeting shRNA. A. RT-qPCR quantification of Rpl13a snoRNAs (relative to Rplp0) in
cytosolic or total extracts. Mean (+SE) for n = 4 independent experiments. B.
Representative western analysis of cytosolic and non-cytosolic fractions for cytosolic
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(HSP90; α-tubulin, TUB) and nuclear (nucleophosmin, NPM) markers. C. Cells were
untreated or treated with 1mM H2O2 for 4h. RT-qPCR quantification of Rpl13a snoRNAs
in cytoplasmic extracts relative to Rplp0 and normalized to levels in untreated ctrl
shRNA-transduced cells. Mean (+SE) for n = 3. D. Quantification of superoxide in
untreated ctrl and NXF3-knockdown cells by dihydroethidium (DHE) staining. Mean
relative fluorescence (RU) + SE for n = 3. E. Representative immunofluorescence
staining for NPM and DAPI staining without or following treatment with H2O2. Scale bar,
50 µM. *, p < 0.05 for NXF3 vs. ctrl shRNA transduced cells; #, p < 0.05 for H2O2
treated vs. untreated; ns, non-significant
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FIGURE 3.3 Knockdown of NXF3 alters Rpl13a snoRNA localization in
cardiomyoblasts. A. Domain structures of NXF1 and NXF3 showing RNA binding
domain (RBD), four leucine-rich repeats (4x LRR), sequence with similarity to nuclear
transport factor 2 (NTF2-like, involved in p15binding), ubiquitin-associated-like domain
(UBA), nuclear localizing sequence (NLS), nuclear export sequence (NES), and CRM1
binding region. B-D. H9c2 cardiomyoblasts were transfected with scrambled siRNA
(ctrl) or two independent siRNAs targeting NXF3 (B, C) or NXF1 (D, E). RT-qPCR
quantification of NXF3 and NXF1 in total RNA (B, D, left graphs) and Rpl13a snoRNAs
in cytosolic RNA (B, D, right graphs) are reported as means (+SE) for n = 3
44

independent experiments. Representative western analysis (C, E) of cytosolic and noncytosolic fractions for cytosolic (HSP90, TUB) and nuclear (NPM) markers as controls
for panels B and D, respectively. *, p < 0.05
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FIGURE 3.4. Overexpression of NXF3 alters Rpl13a snoRNA localization in
fibroblasts. NIH 3T3 fibroblasts were transfected with control plasmid (GFP) or plasmid
encoding NXF3-GFP or NXF1-GFP. A. Representative western analysis and flow
cytometric analysis following transfection. Mean (+SE) for n = 3. B. RT-qPCR of
cytosolic Rpl13a snoRNAs. Mean (+SE) for n = 3. C. Representative western analysis
of cytosolic and non-cytosolic fractions for cytosolic (HSP90, TUB) and nuclear (NPM)
markers. D. RT-qPCR quantification of murine NXF3 in total RNA following transfection
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of rat cardiomyoblasts (left graph) and corresponding quantification of Rpl13a snoRNAs
in cytosolic RNA (right graph) are reported as means (+SE) for n = 3. *, p < 0.05.
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FIGURE 3.5. NXF3- and NXF1-GFP can be immunoprecipitated using α-GFP.
Immunoprecipitation with α-GFP or rabbit IgG as control was analyzed by western blot
analysis using α-GFP. A. H9c2 cardiomyoblasts were transfected with control plasmid
(GFP) or plasmid encoding NXF3-GFP. B. NIH3T3 fibroblasts were transfected with
control plasmid (GFP) or plasmid encoding NXF3-GFP. C. NIH 3T3 fibroblasts were
transfected with control plasmid (GFP) or plasmid encoding NXF1-GFP.
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Figure 3.6. NXF3 and NXF1 associate with snoRNAs. A. Co-immunoprecipitating
RNA was isolated and quantified by RT-qPCR for Rpl13a snoRNAs in H9c2
cardiomyoblasts transfected with control plasmid (GFP) or plasmid encoding NXF3GFP. B,C. NIH3T3 fibroblasts were transfected with control plasmid (GFP) or plasmid
encoding NXF3-GFP or NXF1-GFP. Co-immunoprecipitating RNA was isolated and
quantified by RT-qPCR for Rpl13a snoRNAs (B) and selected box C/D and box H/ACA
snoRNAs (C). Graphs report enrichment in NXF3-GFP-transfected or NXF1-GFP-transfected cells over GFP-transfected cells. Means (+SE) for n = 3 independent
experiments. *, p < 0.05
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Table 3.6A Quality of RNA Sequencing Data

Input 1
Input 2
Input 3
Pulldown 1
Pulldown 2
Pulldown 3

Total
reads
12622611
8494636
15845764
3321562
19470767
13412207

Avg
quality
36.56
36.53
36.57
36.63
36.55
36.55

% G/C
42.81
43.23
42.99
43.40
42.52
42.45
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Total
aligned
6914155
3561964
7717165
1498556
12639529
6330452

%
Aligned
54.78
41.93
48.70
45.12
64.92
47.20

% rRNA
49.32
36.13
42.95
38.85
59.51
43.59

Table 3.6B Distribution of Non-Ribosomal RNA Reads
RNA

Input (%)

Pulldown (%)

Significance

C/D snoRNA
H/ACA snoRNA
lncRNA
miRNA
mRNA
Other

92.45 ± 0.93
6.26 ± 0.79
0.24 ± 0.04
0.27 ± 0.02
0.76 ± 0.09
0.02 ± 0.00

91.92 ± 1.69
6.98 ± 1.50
0.33 ± 0.08
0.19 ± 0.07
0.59 ± 0.13
0.00 ± 0.00

NS
NS
NS
NS
NS
NS
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Table 3.6C Most Abundant Immunoprecipitating snoRNAs
Gene ID

LSMean
(Pulldown)

LSMean
(Input)

Enrichment
(pulldown/input)

FDR

P-value

Significance

Snord55
Snord44
Z23
Snord24
Snord2
Snora48
Snord45
Z19
Z15
Snord14e
Snord4a
Snord96a
Snord45c
Snord74
Snord32a
Snord14d
Snord14c
Snord73
Snord34
Snord95
Snord1b
Snord35a
Snord113
Snord82
Snord104
DQ267100
Snord100
Snord1c
Snord12
Snord33
Snord15b
Snord123
Rnu73b
DQ267102
Snord92
Snord37
AF357426
AF357425
Snord15a
AF357355
Snord110
Snora24
Z21
Gm24148
Snord22
Snora52
Snora16a

421533.33
299548.00
229492.67
208143.67
144321.67
120987.00
97189.00
76795.67
70041.33
56763.00
50187.00
29898.00
26526.00
23828.33
23639.33
18182.33
14650.00
11345.33
10821.67
9882.33
8164.00
5050.33
4508.67
4491.33
3567.00
2406.67
2392.67
2302.00
2044.33
1497.33
1280.00
1268.67
980.33
963.33
746.67
650.00
647.33
505.67
478.00
317.33
297.33
271.51
220.00
198.00
189.33
180.00
163.33

422930.00
218320.33
218334.00
156536.67
150285.33
114743.00
82084.33
86895.67
78718.67
51011.67
32887.00
36448.00
17509.67
20331.67
36071.67
14849.67
11996.67
10193.33
9770.33
7793.67
8715.67
7777.33
5383.67
3655.33
2764.67
3323.33
2097.33
2378.67
862.67
881.00
1128.67
1322.00
984.00
1123.33
466.00
674.67
366.67
525.67
545.67
388.00
158.00
742.24
144.67
134.00
340.00
212.67
144.00

1.00
1.37
1.05
1.33
0.96
1.05
1.18
0.88
0.89
1.11
1.53
0.82
1.51
1.17
0.66
1.22
1.22
1.11
1.11
1.27
0.94
0.65
0.84
1.23
1.29
0.72
1.14
0.97
2.37
1.7
1.13
0.96
1.00
0.86
1.60
0.96
1.77
0.96
0.88
0.82
1.88
0.37
1.52
1.48
0.56
0.85
1.13

1.00
0.99
0.99
0.99
1.00
0.99
0.99
0.99
0.99
0.99
1.00
1.00
0.99
0.99
1.00
0.99
0.99
0.99
1.00
1.00
1.00
1.00
0.99
1.00
1.00
0.99
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.99
1.00
0.99
0.99
0.99
1.00
0.99
1.00
1.00
0.99
1.00
1.00
1.00
1.00

0.84
0.87
0.56
0.90
0.64
0.87
0.77
0.57
0.64
0.90
0.91
0.53
0.99
0.74
0.62
0.79
0.77
0.61
0.61
0.84
0.49
0.43
0.81
0.97
0.98
0.50
0.76
0.42
0.34
0.87
0.99
0.45
0.47
0.74
0.88
0.61
0.98
0.81
0.69
0.87
0.62
0.07
0.93
0.78
0.24
0.42
0.75

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
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CHAPTER FOUR:
NXF3 as a point of regulation of transport
4.1 INTRODUCTION
Eukaryotic cells are divided into distinct compartments that have specific functions. This
compartmentalization is important in determining the environments in which proteins
and RNA operate. The localization of proteins and RNA within the cell can impact their
functions. Therefore, transport between organelles and the resulting subcellular
distribution is tightly regulated

96

. An understanding of the regulation of the

nucleocytplasmic transport of NXF3 and the snoRNAs, may provide insights into
snoRNA roles outside of the nucleus.

Forskolin (FSK) is a labdane diterpene drug that activates adenylyl cyclase, leading to
an increase in levels of intracellular cyclic AMP

97

. Protein kinase A (PKA) activation is

dependent on cyclic AMP, thus allowing the catalytic subunits of PKA to phosphorylate
many substrate proteins. The resulting phosphorylation of proteins can result in their
translocation. For example, phosphorylation can increase the affinity between cargo and
its specific import factor, thus increasing nuclear import. Additionally, phosphorylation of
a protein can induce a conformational change that exposes an NLS. It is not known
whether FSK impacts snoRNA trafficking or the function of NXF3 through
phosphorylation. However, it is important to note that forskolin can also activate
exchange proteins activated by cAMP and activate calcium channels 98-101.

53

Our work has shown that distribution of snoRNAs between the nucleus and cytoplasm is
perturbed by treatment with doxorubicin (DOX). DOX is an anthracycline chemotherapy
drug that induces high levels of reactive oxygen species (ROS)

47,83

. The mechanism

whereby ROS in general or DOX in specific alters distribution of snoRNAs is not known.

The experiments described below were undertaken to characterize the effects of FSK
and DOX on snoRNA localization and to determine whether effects of these agents may
be mediated through the actions of NXF3.

4.2 RESULTS
4.2.1 Forskolin decreases cytosolic Rpl13a snoRNAs and increases NXF3-Rpl13a
snoRNA association
Treatment of H9c2 cardiomyoblasts or NIH 3T3 fibroblasts for 1 h with FSK significantly
decreased cytosolic Rpl13a snoRNA levels compared to DMSO-treated controls
(Figure 4.1). To test whether FSK affects NXF3 localization or its association with
snoRNAs, we transfected NIH 3T3 fibroblasts with a plasmid for expression of NXF3GFP. Similar to our findings with untransfected cells, and independent of the effects of
NXF3 overexpression itself, cells over-expressing NXF3-GFP had decreased cytosolic
snoRNA abundance following 1 h treatment with FSK (Figure 4.2 A and B). Moreover,
FSK increased association of NXF3-GFP with the Rpl13a snoRNAs (Figure 4.2C).
Concomitantly, immunofluorescence microscopy revealed increased nuclear localization
of NXF3-GFP (Figure 4.2D). Together these observations are consistent with a model
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of NXF3-mediated trafficking of snoRNAs from the nucleus to the cytoplasm that is
regulated by FSK.

4.2.2 NXF3 phosphorylation does not change during forskolin treatment
FSK is a natural compound that activates cyclic AMP signaling through both PKAdependent and PKA-independent mechanisms that could lead to downstream
phosphorylation cascades. Moreover, cAMP regulation of nucleocytoplasmic transport
can be mediated through post-translational modifications of transporters, such as
phosphorylation. Using algorithms for prediction of phosphorylation sites, we identified
several

potential

sites

for

phosphorylation

by

PKA

and

other

kinases

[http://kinasephos2.mbc.nctu.edu.tw/]. We performed an immunoprecipitation of NXF3GFP before and after FSK treatment. Monoclonal antibodies specific for threonine-,
serine-, or tyrosine-phosphorylation sites was used to determine whether NXF3-GFP
phosphorylation levels change after FSK treatment. While each of these antiphosphoantibodies recognizes immunoprecipitated NXF3-GFP, we did not detect any significant
changes in phosphorylation levels after FSK treatment (Figure 4.3).

4.2.3 Doxorubicin increases cytosolic Rpl13a snoRNAs and decreases NXF3Rpl13a snoRNA association
Previously, we showed that treatment of cells with the chemotherapy drug doxorubicin
(DOX) induces nucleolar stress and increases cytosolic Rpl13a snoRNAs

47

. We

hypothesized that DOX treatment might also regulate association between NXF3-GFP
and the Rpl13a snoRNAs. As observed previously in untransfected cells
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45,47

, treatment

with DOX for 1 h increased cytosolic snoRNA levels in NXF3-GFP overexpressing cells
(Figure 4.4 A and B). Furthermore, DOX decreased association between NXF3-GFP
and the Rpl13a snoRNAs (Figure 4.4C). Although the wide fluorescence emission
range of DOX confounds immunofluorescence microscopy approaches, analysis of
subcellular fractions of NXF3-GFP expressing cells revealed that the drug decreases
nuclear localization of NXF3 (Figure 4.4D). Thus, a treatment that promotes
cytoplasmic accumulation of snoRNAs also perturbs localization of NXF3 and its
association with snoRNA cargo.

4.2.4 Forskolin effect on snoRNA localization is dependent on NXF3
To determine whether the FSK- or DOX-induced changes in localization of Rpl13a
snoRNAs were dependent on NXF3, H9c2 rat cardiomyoblasts were transiently
transfected with siRNA to knockdown NXF3 (Figure 4.5A and C) and then treated with
FSK or DOX. Although FSK decreased cytosolic Rpl13a snoRNAs as expected in
control siRNA-transfected cells, this effect was abrogated when NXF3 was knocked
down (Figure 4.5B). In contrast, DOX-induced increases in cytosolic U32a, U33, and
U34 were preserved in the setting of knockdown of NXF3 (Figure 4.5D). As reported
previously, DOX did not cause cytosolic accumulation of U35a

47

. Taken together, our

data are most consistent with a model in which FSK action to diminish cytoplasmic
snoRNAs is dependent on NXF3.
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4.3 CONCLUSIONS
Our studies provide new evidence that FSK regulates the association of snoRNAs and
the transport protein, NXF3, as well as the trafficking of both snoRNAs and NXF3.
Furthermore, NXF3 is required for acute regulation of nuclear snoRNA import by FSK.
On the other hand, lack of dependence of DOX-stimulated snoRNA export on NXF3
suggests that this transport limb may not depend on NXF3. This data suggest a model
in which snoRNAs are continuously cycled between the nucleus and cytosol under
basal conditions. NXF3 efficiently returns the snoRNAs back to the nucleus. FSK
treatment increases the association between NXF3 and the snoRNAs, and signals the
NXF3-snoRNA complex to increase its localization into the nucleus, thus depleting the
cytosolic levels of snoRNAs. While DOX treatment raises cytosolic levels of snoRNAs,
this function appears to be indpenedent of NXF3 function (Figure 4.6).
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4.4 FIGURES

Figure

4.1

Forskolin

decreases

cytosolic

Rpl13a

snoRNA

levels.

H9c2

cardiomyoblasts (A, B) and NIH 3T3 fibroblasts (C, D) were treated with 10 µM forskolin
(FSK) or vehicle (DMSO) for 1 h. A, C. Quantification of cytosolic Rpl13a snoRNAs
relative to Rplp0 by RT-qPCR. Mean (+SE) for n = 3 independent experiments B, D.
Representative western analysis of cytosolic and non-cytosolic fractions for cytosolic
(HSP90, TUB) and nuclear (NPM) markers. *, p < 0.05
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Figure 4.2 Forskolin increases NXF3-GFP-snoRNA association and nuclear
localization of NXF3-GFP. NIH 3T3 fiboroblasts were transfected with control plasmid
(GFP) or plasmid encoding NXF3-GFP and subsequently treated with vehicle (DMSO)
or 10 µM FSK for 1 h. A. Cytosolic Rpl13a snoRNAs were quantified by RT-qPCR
relative to Rplp0 in DMSO treated cells. Mean (+SE) for n = 3 independent experiments.
B. Representative western analysis of cytosolic and non-cytosolic fractions for cytosolic
(HSP90, TUB) and nuclear (NPM) markers. C. Following immunoprecipitation with αGFP, Rpl13a snoRNAs were quantified by RT-qPCR. Graph reports snoRNA
abundance in immunoprecipitates from NXF3-GFP-transfected cells relative to GFPtransfected controls. Mean (+SE) for n = 3 independent experiments. D. Representative
mmunofluorescence micrographs show NXF3-GFP localization. Graph reports summary

59

immunofluorescence data from n = 3 independent experiments. Cells were counted
from 20 independent fields per treatment. Scale bar, 50 µM. *, p < 0.05.
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Figures 4.3 Forskolin does not change NXF3-GFP phosphorylation levels. NIH 3T3
fibroblasts were transfected with a plasmid encoding NXF3-GFP and compared to
untreated, non-transfected cells. Transfected cells were treated with or without 10 µM
FSK for 1 h. A. Representative western blot of immunoprecipitation with α-GFP was
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analyzed using α-GFP to demonstrate efficient pulldown of NXF3-GFP. B-D.
Representative western blots of immunoprecipitation with α-GFP was analyzed using αGFP or specified anti-phospho-threonine (B), anti-phospho-serine (C), and antiphospho-tyrosine (D) antibodies.
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Figure 4.4 Doxorubicin increases cytosolic snoRNAs and decreases NXF3
association with Rpl13a snoRNAs. H9c2 cardiomyoblasts were transfected with
plasmids encoding NXF3-GFP or GFP as control and then were untreated (UT) or
treated with 20 µM doxorubicin (DOX) for 1 h. A, B. Cytosolic snoRNAs quantified by
RT-qPCR relative to Rplp0 in NXF3-GFP-transfected cells. Graph (A) shows mean
(+SE) for n = 4 independent experiments. Representative western analysis of cytosolic
and non-cytosolic fractions for cytosolic (HSP90, TUB) and nuclear (NPM) markers (B).
C. Following immunoprecipitation with α-GFP, Rpl13a snoRNAs were quantified by RTqPCR. Graph reports snoRNA abundance in immunoprecipitates from NXF3-GFPtransfected cells relative to GFP-transfected controls. Mean (+SE) for n = 3. D. NXF363

GFP localization before and after DOX treatment assessed by digitonin extraction.
Representative western analysis and graphs showing summary densitometric analysis
from n = 3 independent experiments. *, p < 0.05; **, p < 0.0001

64

Figure 4.5 Forskolin effect on snoRNA localization is dependent on NXF3. H9c2
cardiomyoblasts were transfected with scrambled siRNA (ctrl) or siRNA targeting NXF3
and subsequently treated for 1 h with 10 µM FSK (A, B) or 20 µM DOX (C, D). A, C.
RT-qPCR quantification of total NXF3 relative to Rplp0. B, D. RT-qPCR quantification of
cytosolic Rpl13a snoRNAs relative to Rplp0. Graphs show mean (+SE) for n = 3
independent experiments. * p < 0.05; ** p < 0.01
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Figure 4.6 Model for NXF3 function. SnoRNAs cycle between the nucleus and
cytoplasm under homeostatic conditions. NXF3 functions as an importer, efficiently
returning snoRNAs to the nucleus and maintaining a high concentration of snoRNAs in
the nucleus relative to the cytoplasm. FSK treatment enhances return of NXF3-snoRNA
complexes to the nucleus, further depleting cytosolic levels of snoRNAs.
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CHAPTER FIVE:
Summary and Discussion
5.1 Summary
There is evidence for a growing number of non-canonical roles for snoRNAs. The
Rpl13a snoRNAs have been shown to mediate the cellular response to metabolic stress
in vitro and in vivo

45,61

. Moreover, these and other snoRNAs accumulate in the cytosol

in response to lipotoxic stress and general oxidative stress

45,47

. The mechanisms

through which snoRNAs act in metabolic stress responses and their RNA targets in this
response are not known. However, it is possible that movement of snoRNAs out of the
nucleus during these stress response pathways enables snoRNAs to target RNAs in
other cellular compartments, including mRNAs. Experimentally disrupting the
nucleocytoplasmic trafficking of the snoRNAs could be used to probe the functions of
snoRNAs in the cytosol. However, mechanisms that govern snoRNA localization and
transport between the nucleus and cytoplasm are poorly understood. Herein, we
demonstrate that the cytosolic accumulation of snoRNAs is regulated by enzyme
NOX4D during doxorubicin treatment. We have also identified NXF3 as a potential
snoRNA nucleocytoplasmic transporter.

5.2 Cytosolic snoRNAs
Previous studies using traditional methods like in situ hybridization and cell fractionation
with detection by northern blotting have shown that snoRNAs localize solely in the
nucleus within Cajal bodies and nucleoli, where they perform their canonical function of
modifying snRNA and rRNA, respectively. Our experiments in which we coupled high
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sensitivity methods of RT-qPCR or RNA-seq to cell fractionation approaches,
demonstrate for the first time that a broad range of snoRNAs is easily detectable in the
cytoplasm under basal, homeostatic conditions. The accumulation of snoRNAs in the
cytoplasm after oxidative stress induced by DOX is rapid and significant. Prior studies
demonstrated that independently transcribed, capped snoRNAs U3, U8 and U13 traffic
between the nucleus and cytoplasm. We show that in addition to these snoRNAs,
intronic, uncapped snoRNAs follow this itinerary and are present in the cytoplasm.

Our data demonstrate that the localization of snoRNAs as a class is regulated at least in
part by NOX and superoxide. Furthermore, our knockdown studies implicate nuclear
localized NOX4D as a key regulator of the nuclear-cytosolic partitioning of Rpl13a
snoRNAs. Under homeostatic conditions, most intronic snoRNAs localize in the
nucleolus, suggesting that following synthesis these snoRNAs either remain within the
nucleus, or if they traffic to the cytoplasm, they are efficiently returned to the nucleus. A
model of tight regulation of cytosolic snoRNA levels is further supported by our lab’s
prior observation that mutant cells with 50% reduction of nuclear Rpl13a snoRNAs
maintain wild-type cytosolic levels of these snoRNAs

46

. The rapid accumulation of

snoRNAs in the cytosol following DOX treatment suggests that nuclear superoxide
promotes redistribution of these snoRNAs into the cytosol. Together, these data
suggest the nucleocytoplasmic trafficking of snoRNAs is highly regulated. Moreover, the
presence of snoRNAs in the cytosol provides a new context in which these snoRNAs
may function in potentially novel roles beyond the modifications of rRNAs and snRNAs.
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5.3 NXF3 as a snoRNA transporter
NXF family members have been identified based on sequence similarity and domain
architecture that for most includes an amino terminal containing RNA binding domain
(RBD), a p15/NXT-heterodimerization domain, and a carboxyl terminal domain involved
in nuclear pore binding

102,103

. The RBD is conserved within the NXF family, however it

is poorly defined for NXF3 as the predicted RBD does not bind to RNA, while the
corresponding domains in NXF1 and NXF2 are capable of binding RNA 104,105. The NXF
family name implies that these proteins are primarily involved in nuclear export. Similar
to NXF1, NXF3 is capable of associating with mRNA

67,73

. Prior studies in which

RNA/protein complexes were isolated in cells transfected with an HA-tagged form of
NXF3 using oligo dT cellulose. The complexes indicated a specific interaction between
poly(A) RNA and HA-NXF3, providing evidence for a role of NXF3 in nuclear export of
mRNA. Furthermore, a leucine-rich NES was identified within NXF3 that recruits CRM1
for its nuclear export activity 73.

Our data support a model in which NXF3 also has a role in importing RNAs to the
nucleus. Knockdown of NXF3 resulted in an increase of cytosolic Rpl13a snoRNAs
while overexpression resulted in a decrease. This data implicated NXF3 as a nuclear
importer, efficiently returning snoRNAs from the cytosol to the nucleus under basal
conditions. On the other hand, knockdown and overexpression of a related family
member, NXF1, did not alter localization of the Rpl13a snoRNAs. Our study is the first
to explore the potential contribution of NXF family members to snoRNA trafficking.
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Together, our data suggest a new role specific to NXF3 as a nuclear importer for
snoRNAs.

In both gain- and loss-of-function studies and in snoRNA binding studies, we compared
NXF3 to NXF1. Although the effects of genetic manipulation on snoRNA localization
were specific for NXF3, both family members are capable of binding the snoRNAs in coimmunoprecipitations. Although the RNA binding domains of NXF3 are not well
characterized, NXF1 contains three RNA binding domains: RNA recognition motif
(RRM), leucine-rich repeat, and NTF2-like domain
binding activity
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. The RRM has non-specific RNA

. It is possible that under the conditions of our immunoprecipitations,

the RRM is capable of binding snoRNAs, even if this family member does not alter
snoRNA distribution in situ. Future structure-function studies of NXF3 that target RNA
binding requirements will provide important insights into this proteins role in snoRNA
trafficking. It will also be of interest to compare NXF3 function in snoRNA trafficking to
NXF family members in addition to NXF1

Some RNA export receptors directly bind to uncapped RNA targets, like miRNA and
tRNA, while others require adaptor proteins like the cab binding complex (CBC) to bind
to the caps of their target RNA, such as snRNA and mRNA
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. Intiguingly, the snRNA

export receptors CRM1 and PHAX are required for the intranuclear transport of
independently transcribed, capped snoRNAs
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. Whether CRM1 and PHAX function

coordinately with NXF3 in snoRNA binding and movement between the nucleus and
cytoplasm will be the subject of future studies.
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While our data suggests that NXF3 regulates the localization of snoRNAs, the most
direct way to demonstrate NXF3 acts as a snoRNA importer is to perform a nuclear
import assay. However, this method has previously been established for proteins, not
snoRNAs. We are currently developing a method with biotin-labeled snoRNAs and
digitonin-permeablized cells. If successful, this method could also be extended to livecell imaging and determine the kinetics of snoRNA transport under different conditions,
like FSK treatment.

5.4 Regulation of NXF3-mediated snoRNA transport
To probe the regulation of snoRNA transport, we treated cells with adenylyl cyclase
activator FSK to increase intracellular levels of cyclic AMP. FSK treatment depleted
cytosolic snoRNAs, an effect that is dependent on NXF3. The increase in NXF3snoRNA association and increase in nuclear localization of NXF3 suggested that the
NXF3 import of snoRNAs is activated by FSK. On the other hand, DOX treatment
increased cytosolic snoRNAs, decreased NXF3-snoRNA association and decreased
nuclear localization of NXF3. However, the DOX effect was not dependent on NXF3.
Together, our data suggest a model in which NXF3 plays a critical role in the return of
snoRNAs from the cytoplasm to the nucleus, a pathway activated by FSK, but does not
participate in DOX-stimulated snoRNA export.

FSK activates cyclic AMP signaling through both PKA-dependent and PKA-independent
mechanisms
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. This could lead to altered post-translational modifications, such as
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phosphorylation of NXF3 or other proteins which function in snoRNA transport. Although
examination of the NXF3 primary sequence suggests a number of potential
phosphorylation sites, FSK did not change NXF3 phosphorylation, as determined using
a panel of α-phospho-tyrosine, α-phospho-serine, and α-phospho-threonine antibodies.
It is possible that the available antibodies lack appropriate specificity or that NXF3 is not
a direct target of FSK. Structure function and proteomics studies will be necessary to
address these possibilities. Furthermore, it is likely that NXF3 is acting in a complex of
proteins similar to other RNA transport pathways and may be associated with another
protein is phosphylated in response to FSK. In the future, immunoprecipitations could
be coupled to mass spectrometry analyses to identify potential NXF3 protein partners.
To confirm NXF3 transport is regulated by cyclic AMP, other inducers of intracellular
levels of cyclic AMP like cholera toxin, phosphodiesterase inhibitors, or PKA inhibitors
could be used
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. Additionally, since FSK can activate cyclic AMP signaling through

PKA-independent mechanisms, treating cells with PKA inhibitors could help narrow
down the mechanism regulating NXF3 transport.

Our data have shown that the snoRNAs interact with NXF1 as well as NXF3. Given that
knockdown and overexpression of NXF1 Does not affect cytosolic snoRNA levels, it will
be of interest to test whether NXF1 association with the Rpl13a snoRNAs changes after
FSK or DOX treatment, similar to NXF3. A finding that NXF1-snoRNA association is
unchanged by FSK or that NXF1 knockdown has no effect on FSK-induced decreases
in cytosolic snoRNAs, would provide further evidence of specificity for NXF3 function in
snoRNA transport.
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5.5 NXF3 and lipotoxicity
The physiological role of NXF3 is unclear. NXF3 has previously been shown to be
dispensable for spermatogenesis, but its role in metabolic stress has not been
investigated

107

. It would be interesting to develop a NXF3 knockdown mouse model

and determine whether tissues are protected from metabolic stress such as lipid
overload. Localization of snoRNAs could be measured from tissues isolated from this
mouse model to confirm that loss of NXF3 alters snoRNA localization

Knockdown of NXF3 confers resistance to lipotoxicity, a process dependent on
snoRNAs from the Rpl13a locus. Loss of NXF3 also alters distribution of these
snoRNAs at baseline and prevents acute increase in cytosolic levels with lipotoxicity.
The abundance of cytoplasmic Rpl13a snoRNAs in NXF3-knockdown cells is
comparable to the levels achieved in control cells following acute lipotoxic exposure.
This suggests that the dynamic change in cytosolic snoRNAs, rather than the absolute
cytoplasmic levels of these non-coding RNAs is a key contributor to lipotoxic injury.
The role of cytosolic snoRNAs is still unknown. Rpl13a snoRNA knockdown cells had
no change in methylation of their predicted rRNA targets, therefore suggesting a
noncanonical targets for the Rpl13a snoRNAs. In situ hybridization studies revealed the
Rpl13a snoRNAs localized in puncta in the cytosol after metabolic stress (CITE
MICHEL 2011). It is possible that the snoRNAs are transported to specific organelles
from the nucleus by NXF3. Future experiments should focus on determination of the
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precise distribution and itinerary of snoRNAs once they leave the nucleus. Identifying
the cytosolic localization could provide insight in the role of snoRNAs outside of the
nucleus. A complete understanding of this new snoRNA biology requires further
dissection of snoRNA trafficking and its regulation. Our identification of a role for NXF3
in regulated snoRNA trafficking represents a first step in this important direction.
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CHAPTER SIX:
Materials and Methods
Materials—Digitonin,

forskolin

(FSK),

phenylmethanesulfonyl

fluoride

(PMSF),

cOmplete protease inhibitor cocktail, and hydrogen peroxide (H2O2) were from Sigma.
Protein A Dynabeads, TURBO DNAse, and dihydroethidium (DHE) were from Thermo
Fisher Scientific. Doxorubicin (DOX) was from Cayman Chemical. TRIzol LS and
SUPERase-IN RNAse inhibitor was from Life Technologies. Dithiothreitol (DTT) was
from CalBiochem and β-mercaptoethanol (BME) from Sigma. Laemmli Sample Buffer
was from Bio-Rad.

Cells—H9c2 cardiomyoblasts and NIH3T3 fibroblasts were from American Type Culture
Collection. Telomerase-immortalized human umbilical vein endothelial cells (HUVECs)
were a gift from Judah Folkman’s laboratory (Harvard Medical School) 108 H9c2 and 3T3
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat
inactivated fetal bovine serum (H9c2) or 10% calf serum (NIH3T3). HUVECs were
maintained in endothelial cell growth medium (Lonza). DOX (20 µM for 1 h), FSK (10
µM for 1h), or H2O2 (1 mM, 4h) were added to media as indicated. Cell viability was
determined using CellTiter-Glo Luminescent Cell Viability Assay (Promega). Basal
cellular ROS was detected by staining cells (100,000 cells per well of 12-well dishes)
with 10 µM DHE and detection using a microplate fluorescence reader (Tecan). Cells
were transfected with plasmid DNA peGFP-1 (Clontech) and NXF3-GFP (gift from the
Sun lab)
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using Lipofectamine 2000 (Life Technologies) and with siRNAs (Life

Technologies Silencer Select) using RNAiMax (Life Technologies), according to the
75

manufacturers’ protocols. Flow cytometric analysis of transfected cells assessed
fluorescence on 104 cells/sample.

shRNA screen—The shRNA screen was performed using a Decode Human GIPZ
Lentiviral

shRNAmir

Library

(Thermo

Scientific).

Immortalized

HUVECs

were

transduced with lentiviral shRNA pools at MOI 0.1 then selected using puromycin.
Puromycin-resistant cells were then treated with 500 µM palmitate for 48 h. After
removing palmitate, cells were grown to form colonies in standard media. Colonies were
hand-picked and re-tested for viability following lipotoxic exposure. For this, cells were
plated in 96-well plate in triplicates (1000 cells per well) and treated with 500 µM
palmitate for 24h. Cells transduced with non-targeting shRNA viral particles were used
as negative control. Colonies with significantly greater viability than control cells were
selected for further analysis. Genomic DNA was isolated from palmitate-resistant cells,
and PCR was used to amplify barcodes corresponding to specific shRNAs for
sequencing. Sequences were compared to the Decode shRNA libraries or analyzed
using BLAST to identify the knocked down genes.

Subcellular Fractionation—For fractionation by detergent extraction, cell pellets were
incubated in digitonin buffer (150mM NaCl, 50mM HEPES pH 7.4, digitonin 100µg/mL,
EDTA 5mM, and SUPERase-In RNase inhibitor 0.1U/µL) for 10 min and centrifuged for
10 min at 2000g to yield a cytoplasmic supernatant and non-cytoplasmic pellet
containing membranes and nuclei 110.
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RNA isolation and quantitative real-time PCR—Total RNA was isolated from
cytoplasmic or non-cytoplasmic fractions and from immunoprecipitates using TRIzol LS
according to manufacturer’s protocol (Life Technologies). cDNA was synthesized with
SuperScript III First-strand Synthesis System (Invitrogen) using oligo-dT priming for
mRNAs and target-specific stem-loop priming snoRNAs

45

. qPCR was performed using

PerfeCTa SYBR Green SuperMix (Quantabio). Relative quantitation of target transcript
expression was calculated using the ddCT method using Rplp0 as an endogenous
control on an ABI 7500 Fast Real-time PCR system.

Immunoprecipitation—Cells were sonicated in 50 mM Tris pH 8.0, 150 mM NaCl, 2
mM EDTA, 0.5% NP40 containing 1X cOmplete protease inhibitor cocktail, 1 mM
PMSF, and 0.1U/µl RNase inhibitor SUPERase-In. After treatment with 0.3U/µl TURBO
DNase, insoluble material was removed by centrifugation at 20,000 x g for 10 min at
4°C. Lysate was incubated with α-GFP (2.5mg/mL) and Protein A Dynabeads for 4 h at
4°C. Complexes were washed four times with lysis buffer. Protein was eluted by
incubation in 2X Laemmli Sample Buffer for western analysis, and RNA was eluted by
incubation in TRIzol LS.

RNA sequencing—For cytosolic snoRNA sequencing experiments, H9c2 cells from 3
independent experiments were treated as indicated, cytosol was recovered by detergent
extraction, and total RNA was isolated using TRIzol LS followed by Qiagen RNeasy
miRNA clean up. Input and immunoprecipitated RNA from 3T3 cells from 3 independent
experiments was isolated and concentrated using RNA Clean & Concentrator-5 (Zymo
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Research). Indexed RNA-sequencing libraries were made using the Illumina TruSeq
small RNA kit. Libraries were amplified with 14 cycles of PCR, pooled, and separated by
PAGE. Products with sizes 30-375 nucleotides were excised and collected from the gel.
Sequencing was performed using an Illumina HiSeq 2500. Demultiplexed data were
analyzed using Partek Flow (build version 6.0.17.0305 Copyright ©; 2017 Partek Inc.,
St. Louis, MO, USA). H9c2 sequences were uploaded to Galaxy. Sequences were
evaluated for quality by FASTQC, trimming was applied to reject scores of <20, and
sequences were clipped to remove adapter sequence. Sequences were aligned to the
rat genome (rn4, Bowtie for Illumina, default settings) and aligned reads were exported
to Partek Genomics Suite (v.6.6) for annotation and quantitative analysis using the rat
genome build that contains snoRNAs (Ensembl Build e69, RGSC3.4.69).
For NXF3 pulldown studies in NIH 3T3 cells, sequences were evaluated for quality and
trimmed to remove adapter sequence. A custom Linux script was used to remove
murine ribosomal sequences according to the Illumina iGenome murine genome
annotation. Remaining sequences were aligned to the murine genome (mm9 Refseq
Transcript 2016-08-01, Bowtie for Illumina, default settings) and aligned reads were
quantified, normalized and annotated. Analysis was limited to genes with >100 aligned
reads. A step-up FDR of 0.05 was considered significant.

Immunoblots—Protein in total, cytoplasmic and non-cytoplasmic fractions was
quantified by bicinchoninic assay (BCA, Thermo Fisher Scientific), separated by SDSPAGE, and immunoblotted. Detection for human nuclear export factor 3 (NXF3; Abcam
ab76430, 1:500), GFP (Abcam ab290, 1:5000), heat shock protein 90 (HSP90; Enzo
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SPA-846, 1:1000), α-tubulin (α-TUB; Sigma T6199, 1:2000), histone H3 (H3; Abcam
ab1791, 1:5000), and nucleophosmin (NPM; Abcam ab37659, 1:1500) used
horseradish peroxidase-conjugated secondary antibodies (Jackson Immuno Research
Laboratories) and Western Lightning Plus-ECL (Perkin Elmer) using a ChemiDoc
Imaging System.

Immunofluorescence—Cells were grown on glass coverslips coated with 0.8% gelatin,
fixed with 4% paraformaldehyde, permeabilized with NP40, and blocked with 200µg/mL
ChromPure IgG (Jackson Immuno Research Laboratories) corresponding to secondary
antibody species. Detection for NPM used α-NPM (Life Technologies 325200; 1:1000)
with secondary Alexa Fluor 350 donkey anti-mouse IgG (Life Technologies A10035;
40µg/mL). GFP transfected cells were grown on glass coverslips and fixed with 4%
paraformaldehyde. Coverslips were mounted on microscope slides using SlowFade
Antifade reagent (Life Technologies S2828). Slides were imaged on a Zeiss Axioskop 2
mot plus microscope with a Zeiss AxioCam MRm camera with a x40 oil immersion
objective at room temperature. Images were acquired using AxioVision Rel. 4.8
software. Images were processed identically using the ImageJ software package
(rsb.info.nih.gov).

Statistics—Biochemical results are presented as mean + SEM for a minimum of 3
independent experiments. Statistical significance was assessed by two-tailed unpaired
t-test. P-value < 0.05 was considered significant.
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